Document:

Exhibit
10.33 

 

UNLESS
PERMITTED UNDER SECURITIES LEGISLATION, THE HOLDER OF THIS SECURITY MUST NOT TRADE THE SECURITY BEFORE JULY 17 2018. 

 

WITHOUT
PRIOR WRITTEN APPROVAL OF THE TSX VENTURE EXCHANGE AND COMPLIANCE WITH ALL APPLICABLE SECURITIES LEGISLATION, THE SECURITIES REPRESENTED
BY THIS CERTIFICATE MAY NOT BE SOLD, TRANSFERRED, HYPOTHECATED OR OTHERWISE TRADED ON OR THROUGH THE FACILITIES OF THE TSX VENTURE
EXCHANGE OR OTHERWISE IN CANADA OR TO OR FOR THE BENEFIT OF A CANADIAN RESIDENT UNTIL JULY 17 2018.

 

NEITHER
THIS SECURITY NOR THE SECURITIES INTO WHICH THIS SECURITY IS CONVERTIBLE HAS BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE
COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT
OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE
REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO,
THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS AS EVIDENCED BY A
LEGAL OPINION OF COUNSEL TO THE TRANSFEROR TO SUCH EFFECT, THE SUBSTANCE OF WHICH SHALL BE REASONABLY ACCEPTABLE TO BORROWER.
THIS SECURITY AND THE SECURITIES ISSUABLE UPON CONVERSION OF THIS SECURITY MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN
ACCOUNT WITH A REGISTERED BROKER-DEALER OR OTHER LOAN WITH A FINANCIAL INSTITUTION THAT IS AN “ACCREDITED INVESTOR”
AS DEFINED IN RULE 501(a) UNDER THE SECURITIES ACT OR OTHER LOAN SECURED BY SUCH SECURITIES.

 

Original
Issue Date: March 16, 2018

 

Principal
Amount: USD$[●]

 

Original
Conversion Price (subject to adjustment herein): CAD$0.10 

 

CONVERTIBLE
NOTE

DUE
September 16, 2018

 

THIS
CONVERTIBLE NOTE is one of a series of duly authorized and validly issued Notes of BRIACELL THERAPEUTICS CORP., corporation
incorporated under the Business Corporations Act (British Columbia), (the “Borrower”), having its principal
place of business at 300-235 15th Street, Vancouver, British Columbia, V7T1L7, due September 16, 2018 (this
note, the “Note” and, collectively with the other notes of such series, the “Notes”).

 

FOR
VALUE RECEIVED, Borrower promises to pay to [●] or its registered assigns (the “Holder”),
with an address at: [●], or shall have paid pursuant to the terms hereunder, the principal sum of USD$[●]
on September 16, 2018, which may be extended by the Holder for up to six (6) additional six (6) month terms at its
sole option (the “Maturity Date”) or such earlier date as this Note is required or permitted to be repaid or
such later date if extended by the Holder as provided hereunder, and to pay interest, if any, to the Holder on the aggregate unconverted
and then outstanding principal amount of this Note in accordance with the provisions hereof.

 

    	 	1	 

    	 

    

 

This
Note is subject to the following additional provisions:

 

Section
1. Definitions. For the purposes hereof, in addition to the terms defined elsewhere in this Note, (a) capitalized terms
not otherwise defined herein shall have the meanings set forth in the Purchase Agreement and (b) the following terms shall have
the following meanings:

 

“Alternate
Consideration” shall have the meaning set forth in Section 5(d).

 

“Applicable
Law” shall mean any law, rule or regulation of any governmental authority or jurisdiction applicable to any party to
this Agreement, as the case may be.

 

“Bankruptcy
Event” means any of the following events: (a) Borrower or any Subsidiary thereof commences a case or other proceeding
under any bankruptcy, reorganization, arrangement, adjustment of debt, relief of debtors, dissolution, insolvency or liquidation
or similar law of any jurisdiction relating to Borrower or any Subsidiary thereof, (b) there is commenced against Borrower or
any Subsidiary thereof any such case or proceeding that is not dismissed within 60 days after commencement, (c) Borrower or any
Subsidiary thereof is adjudicated insolvent or bankrupt or any order of relief or other order approving any such case or proceeding
is entered, (d) Borrower or any Subsidiary thereof suffers any appointment of any custodian or the like for it or any substantial
part of its property that is not discharged or stayed within 60 calendar days after such appointment, (e) Borrower or any Subsidiary
thereof makes a general assignment for the benefit of creditors, (f) Borrower or any Subsidiary thereof calls a meeting of its
creditors with a view to arranging a composition, adjustment or restructuring of its debts or (g) Borrower or any Subsidiary thereof,
by any act or failure to act, expressly indicates its consent to, approval of or acquiescence in any of the foregoing or takes
any corporate or other action for the purpose of effecting any of the foregoing.

 

“Beneficial
Ownership Limitation” shall have the meaning set forth in Section 4(d).

 

“Buy-In”
shall have the meaning set forth in Section 4(c)(v).

 

“Change
of Control Transaction” means, other than by means of conversion or exercise of the Notes and the Securities issued
together with the Notes, the occurrence after the date hereof of any of (a) an acquisition after the date hereof by an individual
or legal entity or “group” (as described in NI 45-106) of effective control (whether through legal or beneficial ownership
of capital stock of Borrower, by contract or otherwise) of in excess of 50% of the voting securities of Borrower, (b) Borrower
merges into or consolidates with any other Person, or any Person merges into or consolidates with Borrower and, after giving effect
to such transaction, the stockholders of Borrower immediately prior to such transaction own less than 50% of the aggregate voting
power of Borrower or the successor entity of such transaction, (c) Borrower sells or transfers all or substantially all of its
assets to another Person and the stockholders of Borrower immediately prior to such transaction own less than 50% of the aggregate
voting power of the acquiring entity immediately after the transaction, (d) a replacement at one time or within a three year period
of more than one-half of the members of the Board of Directors which is not approved by a majority of those individuals who are
members of the Board of Directors on the Original Issue Date (or by those individuals who are serving as members of the Board
of Directors on any date whose nomination to the Board of Directors was approved by a majority of the members of the Board of
Directors who are members on the date hereof), or (e) the execution by Borrower of an agreement to which Borrower is a party or
by which it is bound, providing for any of the events set forth in clauses (a) through (d) above.

 

    	 	2	 

    	 

    

 

“Closing
Price” means on any particular date (a) the last reported closing bid price per share of Common Stock on such date on
the Trading Market (as reported by Bloomberg L.P. or (b) if there is no such price on such date, then the closing bid price on
the Trading Market on the date nearest preceding such date (as reported by Bloomberg L.P. at 4:15 p.m. (Toronto time)), or (c)
if the Common Stock is not then listed or quoted on a Trading Market and if prices for the Common Stock are then reported in the
“pink sheets” published by Pink OTC Markets, Inc. (or a similar organization or agency succeeding to its functions
of reporting prices), the most recent bid price per share of the Common Stock so reported, or (d) if the shares of Common Stock
are not then publicly traded the fair market value of a share of Common Stock as determined by an independent appraiser selected
in good faith by the Holder and reasonably acceptable to Borrower, the fees and expenses of which shall be paid by Borrower.

 

“Conversion”
shall have the meaning ascribed to such term in Section 4.

 

“Conversion
Date” shall have the meaning set forth in Section 4(a).

 

“Conversion
Price” shall have the meaning set forth in Section 4(b).

 

“Conversion
Shares” means, collectively, the shares of Common Stock issuable upon conversion of the Principal Amount and accrued
interest on this Note in accordance with the terms hereof.

 

“Dilutive
Issuance” shall have the meaning set forth in Section 5(e).

 

“Equity
Conditions” means, during the period in question, (a) Borrower shall have duly honored all conversions scheduled to
occur or occurring by virtue of one or more Notices of Conversion of the Holder on or prior to the dates so requested or required,
if any, (b) Borrower shall have paid all liquidated damages and other amounts owing to the applicable Holder in respect of this
Note and the other Transaction Documents, (c) either (y) there is an effective registration statement pursuant to which the Holders
are permitted to utilize the prospectus thereunder to resell all of the Conversion Shares issuable pursuant to the Transaction
Documents (and Borrower believes, in good faith, that such effectiveness will continue uninterrupted for the foreseeable future),
and Company counsel has delivered to the Company’s transfer agent and Holder a standing, written unqualified opinion that
resales may then be made by the Holder of all of the Holders Conversion Shares pursuant to such effective registration statement,
or (z) the Interest Shares may be issued without any restrictive legend and sold as free-trading shares not subject to any or
further restrictions as to amount or manner of sale, (d) the Common Stock is listed or traded on a Trading Market, (e) there is
a sufficient number of authorized, but unissued and otherwise unreserved, shares of Common Stock for the issuance of all of the
shares then issuable pursuant to the Transaction Documents, (f) an Event of Default has not occurred, whether or not such Event
of Default has been cured, (g) there is no existing event which, with the passage of time or the giving of notice, would constitute
an Event of Default, (h) the issuance of the shares in question to the applicable Holder would not exceed the Beneficial Ownership
Limitation, (i) there has been no public announcement of a pending or proposed Fundamental Transaction or Change of Control Transaction
that has not been consummated, and (j) the applicable Holder is not in possession of any information provided by Borrower that
constitutes, or may constitute, material non-public information.

 

“Event
of Default” shall have the meaning set forth in Section 8(a).

 

    	 	3	 

    	 

    

 

“Fundamental
Transaction” shall have the meaning set forth in Section 5(d).

 

“Interest
Payment Date” shall have the meaning set forth in Section 2(a).

 

“Interest
Share Amount” shall have the meaning set forth in Section 2(a).

 

“Mandatory
Default Amount” means the sum of (a) the greater of (i) the outstanding principal amount of this Note divided by the
Conversion Price on the date the Mandatory Default Amount is either (A) demanded (if demand or notice is required to create an
Event of Default) or otherwise due or (B) paid in full, whichever has a lower Conversion Price, multiplied by the VWAP on the
date the Mandatory Default Amount is either (x) demanded, (y) due, or (z) paid in full, whichever is highest, or (ii) 100% of
the outstanding principal amount of this Note plus (b) all other amounts, costs, expenses and liquidated damages due in respect
of this Note.

 

“New
York Courts” shall have the meaning set forth in Section 9(d).

 

“Note
Register” shall have the meaning set forth in Section 2(c).

 

“Notice
of Conversion” shall have the meaning set forth in Section 4(a).

 

“Original
Issue Date” means the date of the first issuance of the Notes, regardless of any transfers of any Note and regardless
of the number of instruments which may be issued to evidence such Notes.

 

“Other
Holders” means holders of Other Notes.

 

“Other
Notes” means Notes nearly identical to this Note issued to other Holders pursuant to the Purchase Agreement.

 

“Permitted
Indebtedness” means (a) any liabilities for borrowed money or amounts owed not in excess of $150,000 in the aggregate
(other than trade accounts payable incurred in the ordinary course of business), (b) all guaranties, endorsements and other contingent
obligations in respect of indebtedness of others, whether or not the same are or should be reflected in the Company’s consolidated
balance sheet (or the notes thereto) not affecting more than $150,000 in the aggregate, except guaranties by endorsement of negotiable
instruments for deposit or collection or similar transactions in the ordinary course of business; and (c) the present value of
any lease payments not in excess of $150,000 due under leases required to be capitalized in accordance with IFRS.

 

“Permitted
Lien” means the individual and collective reference to the following: (a) Liens for taxes, assessments and other governmental
charges or levies not yet due or Liens for taxes, assessments and other governmental charges or levies being contested in good
faith and by appropriate proceedings for which adequate reserves (in the good faith judgment of the management of Borrower) have
been established in accordance with IFRS, (b) Liens imposed by law which were incurred in the ordinary course of Borrower’s
business, such as carriers’, warehousemen’s and mechanics’ Liens, statutory landlords’ Liens, and other
similar Liens arising in the ordinary course of Borrower’s business, and which (x) do not individually or in the aggregate
materially detract from the value of such property or assets or materially impair the use thereof in the operation of the business
of Borrower and its consolidated Subsidiaries or (y) are being contested in good faith by appropriate proceedings, which proceedings
have the effect of preventing for the foreseeable future the forfeiture or sale of the property or asset subject to such Lien,
and (c) Liens in connection with Permitted Indebtedness under clauses (a) and (b) thereunder, and Liens incurred in connection
with Permitted Indebtedness under clause (c) thereunder, provided that such Liens are not secured by assets of Borrower or its
Subsidiaries other than the assets so acquired or leased.

 

    	 	4	 

    	 

    

 

“Purchase
Agreement” means the Securities Purchase Agreement, dated as of February __, 2018 among Borrower and the original Holders,
as amended, modified or supplemented from time to time in accordance with its terms.

 

“Securities
Act” means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.

 

“Share
Delivery Date” shall have the meaning set forth in Section 4(c)(ii).

 

“Successor
Entity” shall have the meaning set forth in Section 5(d).

 

“Trading
Day” means a day on which the principal Trading Market is open for trading.

 

“Trading
Market” means any of the following markets or exchanges on which the Common Stock is listed or quoted for trading on
the date in question: the TSX Venture Exchange, the NYSE MKT, the NASDAQ Capital Market, the NASDAQ Global Market, the NASDAQ
Global Select Market, the New York Stock Exchange, the OTC Bulletin Board, the OTCQB, or the OTCQX (or any successors to any of
the foregoing).

 

“VWAP”
means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock is then
listed or quoted on a Trading Market, the daily volume weighted average price of the Common Stock for such date (or the nearest
preceding date) on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg L.P. (based
on a Trading Day from 9:30 a.m. (Toronto time) to 4:02 p.m. (Toronto time)), (b) if any of the NASDAQ markets or exchanges is
not a Trading Market, the volume weighted average price of the Common Stock for such date (or the nearest preceding date) on the
OTC Bulletin Board, (c) if the Common Stock is not then listed or quoted for trading on the OTC Bulletin Board and if prices for
the Common Stock are then reported on the OTCQX, OTCQB or OTC Pink Marketplace maintained by the OTC Markets Group, Inc. (or a
similar organization or agency succeeding to its functions of reporting prices), the volume weighted average price of the Common
Stock on the first such facility (or a similar organization or agency succeeding to its functions of reporting prices), or (d)
in all other cases, the fair market value of a share of Common Stock as determined by an independent appraiser selected in good
faith by the Purchasers of a majority in interest of the Securities then outstanding and reasonably acceptable to Borrower, the
fees and expenses of which shall be paid by Borrower.

 

Section
2. General.

 

a)
Interest in Cash or in Kind. Holder shall be entitled to receive, and Borrower shall pay, cumulative interest on the outstanding
principal amount of this Note compounded daily at the annual rate of five percent (5%) (as subject to increase as set forth in
this Note) from the Original Issue Date through the Maturity Date. Interest shall be payable on each March 31, June 30, September
30 and December 31 and on the Maturity Date when all amounts outstanding in connection with this Note shall be due and payable
(each an “Interest Payment Date”) (if any Interest Payment Date is not a Trading Day, the applicable payment
shall be due on the next succeeding Trading Day) in cash or provided Borrower has given Holder written notice of its intention
to do so at least ten (10) Trading Days prior to the relevant Interest Payment Date, at the election of the Borrower, such interest
may be paid in duly authorized, validly issued, fully paid and non-assessable shares of Common Stock, or a combination thereof
(the amount to be paid in shares of Common Stock, the “Interest Share Amount”). The Interest Share Amount will
be determined by the Market Price (as such term is defined in the TSX Venture Exchange Corporate Finance Manual) of Common Stock
on the applicable Interest Payment Date.

 

    	 	5	 

    	 

    

 

[This
has been removed as it contravenes the rules of the TSX Venture Exchange].

 

b)
Payment Grace Period. The Borrower shall not have any grace period to pay any monetary amounts due under this Note.

 

c)
Conversion Privileges. The Conversion Rights set forth in Section 4 shall remain in full force and effect immediately from
the date hereof and until the Note is paid in full regardless of the occurrence of an Event of Default. This Note shall be payable
in full on the Maturity Date, unless previously converted into Common Stock in accordance with Section 4 hereof.

 

d)
Application of Payments. Interest, if any, on this Note shall be calculated on the basis of a 360-day year and the actual
number of days elapsed. Payments made in connection with this Note shall be applied first to amounts due hereunder other than
principal and interest, thereafter to interest and finally to principal.

 

e)
Pari Passu. Except as otherwise set forth herein, all payments made on this Note and the Other Notes and all actions taken
by the Borrower with respect to this Note and the Other Notes, shall be made and taken pari passu with respect to this
Note and the Other Notes and the Holders thereof.

 

f)
Manner and Place of Payment. Principal and interest, if any, on this Note and other payments in connection with this Note
shall be payable at the Holder’s offices as designated above in lawful money of the United States of America in immediately
available funds without set-off, deduction or counterclaim. Upon assignment of the interest of Holder in this Note, Borrower shall
instead make its payment pursuant to the assignee’s instructions upon receipt of written notice thereof. Except as set forth
herein, this Note may not be prepaid or mandatorily converted without the consent of the Holder.

 

g)
Extension of Term. At its sole election, the Holder may extend this Note for up to six additional six-month terms by providing
written notice to the Borrow at least ten days prior to the maturity date of the initial term or any extension thereof.

 

Section
3. Registration of Transfers and Exchanges.

 

a)
Different Denominations. This Note is exchangeable for an equal aggregate principal amount of Notes of different authorized
denominations, as requested by the Holder surrendering the same. No service charge will be payable for such registration of transfer
or exchange.

 

b)
Investment Representations. This Note has been issued subject to certain investment representations of the original Holder
set forth in the Purchase Agreement and may be transferred or exchanged only in compliance with the Purchase Agreement and Applicable
Law.

 

c)
Reliance on Note Register. Prior to due presentment for transfer to Borrower of this Note, Borrower and any agent of Borrower
may treat the Person in whose name this Note is duly registered on the Note Register as the owner hereof for the purpose of receiving
payment as herein provided and for all other purposes, whether or not this Note is overdue, and neither Borrower nor any such
agent shall be affected by notice to the contrary.

 

    	 	6	 

    	 

    

 

Section
4. Conversion.

 

a)
Voluntary Conversion. At any time after the Original Issue Date until this Note is no longer outstanding, this Note and
accrued interest shall be convertible, in whole or in part, into shares of Common Stock and one Warrant per share of Common Stock
issued at the option of the Holder, at any time and from time to time (subject to the conversion limitations set forth in Section
4(d) hereof). The Holder shall effect conversions by delivering to Borrower a Notice of Conversion, the form of which is attached
hereto as Annex A (each, a “Notice of Conversion”), specifying therein the principal amount of this
Note to be converted and the date on which such conversion shall be effected (such date, the “Conversion Date”).
If no Conversion Date is specified in a Notice of Conversion, the Conversion Date shall be the date that such Notice of Conversion
is deemed delivered hereunder. To effect conversions hereunder, the Holder shall not be required to physically surrender this
Note to Borrower unless the entire principal amount of this Note has been so converted. Conversions hereunder shall have the effect
of lowering the outstanding principal amount of this Note in an amount equal to the applicable conversion. The Holder and Borrower
shall maintain records showing the principal amount(s) converted and the date of such conversion(s). Borrower may deliver an objection
to any Notice of Conversion within two (2) Trading Days of delivery of such Notice of Conversion. In the event of any dispute
or discrepancy, the records of the Holder shall be controlling and determinative in the absence of manifest error. The Holder,
and any assignee by acceptance of this Note, acknowledge and agree that, by reason of the provisions of this paragraph, following
conversion of a portion of this Note, the unpaid and unconverted principal amount of this Note may be less than the amount stated
on the face hereof.

 

b)
Conversion Price. The conversion price for the principal and interest in connection with voluntary conversions by the Holder
shall be CAD$0.10, subject to adjustment herein (the “Conversion Price”).

 

c)
Mechanics of Conversion.

 

i.
Conversion Shares Issuable Upon Conversion of Principal Amount. The number of Conversion Shares issuable upon a conversion
hereunder shall be determined by the quotient obtained by dividing (x) the outstanding principal amount of this Note to be converted
by (y) the Conversion Price.

 

ii.
Delivery of Certificate Upon Conversion. Not later than three (3) Trading Days after each Conversion Date (the “Share
Delivery Date”), Borrower shall deliver, or cause to be delivered, to the Holder a certificate or certificates representing
the Conversion Shares which, on or after the four month anniversary of the Original Issue Date, shall be free of restrictive legends
and trading restrictions (other than those which may then be required by the Purchase Agreement and under any Applicable Law representing
the number of Conversion Shares being acquired upon the conversion of this Note. On or after the earlier of the four month anniversary
of the Original Issue Date, Borrower shall use its best efforts to deliver any certificate or certificates required to be delivered
by Borrower under this Section 4(c) electronically through the Depository Trust Company or another established clearing corporation
performing similar functions.

 

    	 	7	 

    	 

    

 

iii.
Failure to Deliver Certificates. If, in the case of any Notice of Conversion, such certificate or certificates are not
delivered to or as directed by the applicable Holder by the Share Delivery Date, the Holder shall be entitled to elect by written
notice to Borrower at any time on or before its receipt of such certificate or certificates, to rescind such Conversion, in which
event Borrower shall promptly return to the Holder any original Note delivered to Borrower and the Holder shall promptly return
to Borrower the Common Stock certificates issued to such Holder pursuant to the rescinded Conversion Notice.

 

iv.
Obligation Absolute. Borrower’s obligations to issue and deliver the Conversion Shares upon conversion of this Note
in accordance with the terms hereof are absolute and unconditional, irrespective of any action or inaction by the Holder to enforce
the same, any waiver or consent with respect to any provision hereof, the recovery of any judgment against any Person or any action
to enforce the same, or any setoff, counterclaim, recoupment, limitation or termination, or any breach or alleged breach by the
Holder or any other Person of any obligation to Borrower or any violation or alleged violation of law by the Holder or any other
Person, and irrespective of any other circumstance which might otherwise limit such obligation of Borrower to the Holder in connection
with the issuance of such Conversion Shares; provided, however, that such delivery shall not operate as a waiver
by Borrower of any such action Borrower may have against the Holder. In the event the Holder of this Note shall elect to convert
any or all of the outstanding principal amount hereof, Borrower may not refuse conversion based on any claim that the Holder or
anyone associated or affiliated with the Holder has been engaged in any violation of law, agreement or for any other reason, unless
an injunction from a court, on notice to Holder, restraining and or enjoining conversion of all or part of this Note shall have
been sought and obtained, and Borrower posts a surety bond for the benefit of the Holder in the amount of 150% of the outstanding
principal amount of this Note, which is subject to the injunction, which bond shall remain in effect until the completion of arbitration/litigation
of the underlying dispute and the proceeds of which shall be payable to the Holder to the extent it obtains judgment. In the absence
of such injunction, Borrower shall issue Conversion Shares or, if applicable, cash, upon a properly noticed conversion. If Borrower
fails for any reason to deliver to the Holder such certificate or certificates pursuant to Section 4(c)(ii) by the Share Delivery
Date, Borrower shall pay to the Holder, in cash, as liquidated damages and not as a penalty, for each $1,000 of principal amount
being converted, $10 per Trading Day (increasing to $20 per Trading Day on the fifth (5th) Trading Day after such liquidated
damages being to accrue) for each Trading Day after such Share Delivery Date until such certificates are delivered or Holder rescinds
such conversion. Nothing herein shall limit a Holder’s right to pursue actual damages or declare an Event of Default pursuant
to Section 8 hereof for Borrower’s failure to deliver Conversion Shares within the period specified herein and the Holder
shall have the right to pursue all remedies available to it hereunder, at law or in equity including, without limitation, a decree
of specific performance and/or injunctive relief. The exercise of any such rights shall not prohibit the Holder from seeking to
enforce damages pursuant to any other Section hereof or under applicable law.

 

    	 	8	 

    	 

    

 

v.
Compensation for Buy-In on Failure to Timely Deliver Certificates Upon Conversion. In addition to any other rights available
to the Holder, if Borrower fails for any reason to deliver to the Holder such certificate or certificates by the Share Delivery
Date pursuant to Section 4(c)(ii), and if after such Share Delivery Date the Holder is required by its brokerage firm to purchase
(in an open market transaction or otherwise), or the Holder or Holder’s brokerage firm otherwise purchases, shares of Common
Stock to deliver in satisfaction of a sale by the Holder of the Conversion Shares which the Holder was entitled to receive upon
the conversion relating to such Share Delivery Date (a “Buy-In”), then Borrower shall (A) pay in cash to the
Holder (in addition to any other remedies available to or elected by the Holder) the amount, if any, by which (x) the Holder’s
total purchase price (including any brokerage commissions) for the Common Stock so purchased exceeds (y) the product of (1) the
aggregate number of shares of Common Stock that the Holder was entitled to receive from the conversion at issue multiplied by
(2) the actual sale price at which the sell order giving rise to such purchase obligation was executed (including any brokerage
commissions) and (B) at the option of the Holder, either reissue (if surrendered) this Note in a principal amount equal to the
principal amount of the attempted conversion (in which case such conversion shall be deemed rescinded) or deliver to the Holder
the number of shares of Common Stock that would have been issued if Borrower had timely complied with its delivery requirements
under Section 4(c)(ii). For example, if the Holder purchases Common Stock having a total purchase price of $11,000 to cover a
Buy-In with respect to an attempted conversion of this Note with respect to which the actual sale price of the Conversion Shares
(including any brokerage commissions) giving rise to such purchase obligation was a total of $10,000 under clause (A) of the immediately
preceding sentence, Borrower shall be required to pay the Holder $1,000. The Holder shall provide Borrower written notice indicating
the amounts payable to the Holder in respect of the Buy-In and, upon request of Borrower, evidence of the amount of such loss.
Nothing herein shall limit a Holder’s right to pursue any other remedies available to it hereunder, at law or in equity
including, without limitation, a decree of specific performance and/or injunctive relief with respect to Borrower’s failure
to timely deliver certificates representing shares of Common Stock upon conversion of this Note as required pursuant to the terms
hereof.

 

vi.
Reservation of Shares Issuable Upon Conversion. Borrower covenants that it will at all times reserve and keep available
out of its authorized and unissued shares of Common Stock for the sole purpose of issuance upon conversion of this Note as herein
provided, free from preemptive rights or any other actual contingent purchase rights of Persons other than the Holder (and the
other holders of the Notes), not less than such aggregate number of shares of the Common Stock as shall (subject to the terms
and conditions set forth in the Purchase Agreement) be issuable (taking into account the adjustments and restrictions of Section
5) upon the conversion of the then outstanding principal amount of this Note on such principal amount. Borrower covenants that
all shares of Common Stock that shall be so issuable shall, upon issue, be duly authorized, validly issued, fully paid and nonassessable.

 

vii.
Fractional Shares. No fractional shares or scrip representing fractional shares shall be issued upon the conversion of
this Note. As to any fraction of a share which the Holder would otherwise be entitled to purchase upon such conversion, Borrower
shall at its election, either pay a cash adjustment in respect of such final fraction in an amount equal to such fraction multiplied
by the Conversion Price or round up to the next whole share.

 

viii.
Transfer Taxes and Expenses. The issuance of certificates for shares of the Common Stock on conversion of this Note shall
be made without charge to the Holder hereof for any documentary stamp or similar taxes that may be payable in respect of the issue
or delivery of such certificates, provided that, Borrower shall not be required to pay any tax that may be payable in respect
of any transfer involved in the issuance and delivery of any such certificate upon conversion in a name other than that of the
Holder of this Note so converted and Borrower shall not be required to issue or deliver such certificates unless or until the
Person or Persons requesting the issuance thereof shall have paid to Borrower the amount of such tax or shall have established
to the satisfaction of Borrower that such tax has been paid. Borrower shall pay all Transfer Agent fees required for same-day
processing of any Notice of Conversion.

 

    	 	9	 

    	 

    

 

d)
Holder’s Conversion Limitations. Borrower shall not effect any conversion of this Note, and a Holder shall not have
the right to convert any portion of this Note, to the extent that after giving effect to the conversion set forth on the applicable
Notice of Conversion, the Holder (together with the Holder’s Affiliates, and any Persons acting as a group together with
the Holder or any of the Holder’s Affiliates) would beneficially own in excess of the Beneficial Ownership Limitation (as
defined below). For purposes of the foregoing sentence, the number of shares of Common Stock beneficially owned by the Holder
and its Affiliates shall include the number of shares of Common Stock issuable upon conversion of this Note with respect to which
such determination is being made, but shall exclude the number of shares of Common Stock which are issuable upon (i) conversion
of the remaining, unconverted principal amount of this Note beneficially owned by the Holder or any of its Affiliates and (ii)
exercise or conversion of the unexercised or unconverted portion of any other securities of Borrower subject to a limitation on
conversion or exercise analogous to the limitation contained herein (including, without limitation, any other Notes or the Warrants)
beneficially owned by the Holder or any of its Affiliates. Except as set forth in the preceding sentence, for purposes of this
Section 4(d), beneficial ownership shall be calculated in accordance with the rules and policies of the TSX Venture Exchange.
To the extent that the limitation contained in this Section 4(d) applies, the determination of whether this Note is convertible
(in relation to other securities owned by the Holder together with any Affiliates) and of which principal amount of this Note
is convertible shall be in the sole discretion of the Holder, and the submission of a Notice of Conversion shall be deemed to
be the Holder’s determination of whether this Note may be converted (in relation to other securities owned by the Holder
together with any Affiliates) and which principal amount of this Note is convertible, in each case subject to the Beneficial Ownership
Limitation. To ensure compliance with this restriction, the Holder will be deemed to represent to Borrower each time it delivers
a Notice of Conversion that such Notice of Conversion has not violated the restrictions set forth in this paragraph and Borrower
shall have no obligation to verify or confirm the accuracy of such determination. In addition, a determination as to any group
status as contemplated above shall be determined in accordance with the rules of the TSX Venture Exchange. For purposes of this
Section 4(d), in determining the number of outstanding shares of Common Stock, the Holder may rely on the number of outstanding
shares of Common Stock as stated in the most recent of the following: (i) Borrower’s most recent periodic or annual report
filed with the TSX Venture Exchange, as the case may be, (ii) a more recent public announcement by Borrower, or (iii) a more recent
written notice by Borrower or Borrower’s transfer agent setting forth the number of shares of Common Stock outstanding.
Upon the written or oral request of a Holder, Borrower shall within three Trading Days confirm orally and in writing to the Holder
the number of shares of Common Stock then outstanding. In any case, the number of outstanding shares of Common Stock shall be
determined after giving effect to the conversion or exercise of securities of Borrower, including this Note, by the Holder or
its Affiliates since the date as of which such number of outstanding shares of Common Stock was reported. The “Beneficial
Ownership Limitation” shall be 9.99% of the number of shares of the Common Stock outstanding immediately after giving
effect to the issuance of shares of Common Stock issuable upon conversion of this Note held by the Holder. The Holder may decrease
the Beneficial Ownership Limitation at any time and the Holder, upon not less than 61 days’ prior notice to Borrower, may
increase the Beneficial Ownership Limitation provisions of this Section 4(d), provided that the Beneficial Ownership Limitation
in no event exceeds 9.99% of the number of shares of the Common Stock outstanding immediately after giving effect to the issuance
of shares of Common Stock upon conversion of this Note held by the Holder and the Beneficial Ownership Limitation provisions of
this Section 4(d) shall continue to apply. Any such increase will not be effective until the 61st day after such notice
is delivered to Borrower. The Beneficial Ownership Limitation provisions of this paragraph shall be construed and implemented
in a manner otherwise than in strict conformity with the terms of this Section 4(d) to correct this paragraph (or any portion
hereof) which may be defective or inconsistent with the intended Beneficial Ownership Limitation contained herein or to make changes
or supplements necessary or desirable to properly give effect to such limitation. The limitations contained in this paragraph
shall apply to a successor holder of this Note.

 

    	 	10	 

    	 

    

 

Section
5. Certain Adjustments.

 

a)
Stock Dividends and Stock Splits. If Borrower, at any time while this Note is outstanding: (i) pays a stock dividend or
otherwise makes a distribution or distributions payable in shares of Common Stock on shares of Common Stock or any Common Stock
Equivalents (which, for avoidance of doubt, shall not include any shares of Common Stock issued by Borrower upon conversion of
the Notes), (ii) subdivides outstanding shares of Common Stock into a larger number of shares, (iii) combines (including by way
of a reverse stock split) outstanding shares of Common Stock into a smaller number of shares or (iv) issues, in the event of a
reclassification of shares of the Common Stock, any shares of capital stock of Borrower, then the Conversion Price shall be multiplied
by a fraction of which the numerator shall be the number of shares of Common Stock (excluding any treasury shares of Borrower)
outstanding immediately before such event, and of which the denominator shall be the number of shares of Common Stock outstanding
immediately after such event. Any adjustment made pursuant to this Section shall become effective immediately after the record
date for the determination of stockholders entitled to receive such dividend or distribution and shall become effective immediately
after the effective date in the case of a subdivision, combination or re-classification.

 

b)
Subsequent Rights Offerings. In addition to any adjustments pursuant to Section 5(a) above, if at any time Borrower grants,
issues or sells any Common Stock Equivalents or rights to purchase stock, warrants, securities or other property pro rata to the
record holders of any class of shares of Common Stock (the “Purchase Rights”), then the Holder will be entitled
to acquire, upon the terms applicable to such Purchase Rights, the aggregate Purchase Rights which the Holder could have acquired
if the Holder had held the number of shares of Common Stock acquirable upon complete conversion of this Note (without regard to
any limitations on exercise hereof, including without limitation, the Beneficial Ownership Limitation) immediately before the
date on which a record is taken for the grant, issuance or sale of such Purchase Rights, or, if no such record is taken, the date
as of which the record holders of shares of Common Stock are to be determined for the grant, issue or sale of such Purchase Rights
(provided, however, to the extent that the Holder’s right to participate in any such Purchase Right would result in the
Holder exceeding the Beneficial Ownership Limitation, then the Holder shall not be entitled to participate in such Purchase Right
to such extent (or beneficial ownership of such shares of Common Stock as a result of such Purchase Right to such extent) and
such Purchase Right to such extent shall be held in abeyance for the Holder until such time, if ever, as its right thereto would
not result in the Holder exceeding the Beneficial Ownership Limitation).

 

 

    	 	11	 

    	 

    

 

c)
Pro Rata Distributions. During such time as this Note is outstanding, if Borrower shall declare or make any dividend whether
or not permitted, or makes any other distribution of its assets (or rights to acquire its assets) to holders of shares of Common
Stock, by way of return of capital or otherwise (including, without limitation, any distribution of cash, stock or other securities,
property or options by way of a dividend, spin off, reclassification, corporate rearrangement, scheme of arrangement or other
similar transaction) (a “Distribution”), at any time after the issuance of this Note, then, in each such case,
the Holder shall be entitled to participate in such Distribution to the same extent that the Holder would have participated therein
if the Holder had held the number of shares of Common Stock acquirable upon complete exercise of this Note (without regard to
any limitations on exercise hereof, including without limitation, the Beneficial Ownership Limitation) immediately before the
date of which a record is taken for such Distribution, or, if no such record is taken, the date as of which the record holders
of shares of Common Stock are to be determined for the participation in such Distribution (provided, however, to
the extent that the Holder’s right to participate in any such Distribution would result in the Holder exceeding the Beneficial
Ownership Limitation, then the Holder shall not be entitled to participate in such Distribution to such extent (or in the beneficial
ownership of any shares of Common Stock as a result of such Distribution to such extent) and the portion of such Distribution
shall be held in abeyance for the benefit of the Holder until such time, if ever, as its right thereto would not result in the
Holder exceeding the Beneficial Ownership Limitation).

 

d)
Fundamental Transaction. If, at any time while this Note is outstanding, (i) Borrower, directly or indirectly, in one or
more related transactions effects any merger or consolidation of Borrower with or into another Person, (ii) Borrower, directly
or indirectly, effects any sale, lease, license, assignment, transfer, conveyance or other disposition of all or substantially
all of its assets in one or a series of related transactions, (iii) any, direct or indirect, purchase offer, tender offer or exchange
offer (whether by Borrower or another Person) is completed pursuant to which holders of Common Stock are permitted to sell, tender
or exchange their shares for other securities, cash or property and has been accepted by the holders of 50% or more of the outstanding
Common Stock, (iv) Borrower, directly or indirectly, in one or more related transactions effects any reclassification, reorganization
or recapitalization of the Common Stock or any compulsory share exchange pursuant to which the Common Stock is effectively converted
into or exchanged for other securities, cash or property, (v) Borrower, directly or indirectly, in one or more related transactions
consummates a stock or share purchase agreement or other business combination (including, without limitation, a reorganization,
recapitalization, spin-off or scheme of arrangement) with another Person whereby such other Person acquires more than 50% of the
outstanding shares of Common Stock (not including any shares of Common Stock held by the other Person or other Persons making
or party to, or associated or affiliated with the other Persons making or party to, such stock or share purchase agreement or
other business combination) (each a “Fundamental Transaction”), then, upon any subsequent conversion of this
Note, the Holder shall have the right to receive, for each Conversion Share that would have been issuable upon such conversion
immediately prior to the occurrence of such Fundamental Transaction (without regard to any limitation in Section 4(d) on the conversion
of this Note), the number of shares of Common Stock of the successor or acquiring corporation or of Borrower, if it is the surviving
corporation, and any additional consideration (the “Alternate Consideration”) receivable as a result of such
Fundamental Transaction by a holder of the number of shares of Common Stock for which this Note is convertible immediately prior
to such Fundamental Transaction (without regard to any limitation in Section 4(d) on the conversion of this Note). For purposes
of any such conversion, the determination of the Conversion Price shall be appropriately adjusted to apply to such Alternate Consideration
based on the amount of Alternate Consideration issuable in respect of one (1) share of Common Stock in such Fundamental Transaction,
and Borrower shall apportion the Conversion Price among the Alternate Consideration in a reasonable manner reflecting the relative
value of any different components of the Alternate Consideration. If holders of Common Stock are given any choice as to the securities,
cash or property to be received in a Fundamental Transaction, then the Holder shall be given the same choice as to the Alternate
Consideration it receives upon any conversion of this Note following such Fundamental Transaction. Borrower shall cause any successor
entity in a Fundamental Transaction in which Borrower is not the survivor (the “Successor Entity”) to assume
in writing all of the obligations of Borrower under this Note and the other Transaction Documents (as defined in the Purchase
Agreement) in accordance with the provisions of this Section 5(d) pursuant to written agreements prior to or contemporaneously
with such Fundamental Transaction and shall, at the option of the holder of this Note, deliver to the Holder in exchange for this
Note a security of the Successor Entity evidenced by a written instrument substantially similar in form and substance to this
Note which is convertible for a corresponding number of shares of capital stock of such Successor Entity (or its parent entity)
equivalent to the shares of Common Stock acquirable and receivable upon conversion of this Note (without regard to any limitations
on the conversion of this Note) prior to such Fundamental Transaction, and with a conversion price which applies the conversion
price hereunder to such shares of capital stock (but taking into account the relative value of the shares of Common Stock pursuant
to such Fundamental Transaction and the value of such shares of capital stock, such number of shares of capital stock and such
conversion price being for the purpose of protecting the economic value of this Note immediately prior to or contemporaneously
with the consummation of such Fundamental Transaction). Upon the occurrence of any such Fundamental Transaction, the Successor
Entity shall succeed to, and be substituted for (so that from and after the date of such Fundamental Transaction, the provisions
of this Note and the other Transaction Documents referring to the “Company” shall refer instead to the Successor Entity),
and may exercise every right and power of Borrower and shall assume all of the obligations of Borrower under this Note and the
other Transaction Documents with the same effect as if such Successor Entity had been named as Borrower herein. Alternatively,
the Holder may demand the Company to redeem its Note at a rate equal to 125% of the principal and interest due thereon, to be
paid in full contemporaneously with consummation of the Fundamental Transaction.

 

    	 	12	 

    	 

    

 

e)
Calculations. All calculations under this Section 5 shall be made to the nearest cent or the nearest 1/100th of a share,
as the case may be. For purposes of this Section 5, the number of shares of Common Stock deemed to be issued and outstanding as
of a given date shall be the sum of the number of shares of Common Stock (excluding any treasury shares of Borrower) issued and
outstanding.

 

f)
Notice to the Holder.

 

i.
Intentionally omitted.

 

ii.
Notice to Allow Conversion by Holder. If (A) Borrower shall declare a dividend (or any other distribution in whatever form)
on the Common Stock, (B) Borrower shall declare a special nonrecurring cash dividend on or a redemption of the Common Stock, (C)
Borrower shall authorize the granting to all holders of the Common Stock of rights or warrants to subscribe for or purchase any
shares of capital stock of any class or of any rights, (D) the approval of any stockholders of Borrower shall be required in connection
with any reclassification of the Common Stock, any consolidation or merger to which Borrower is a party, any sale or transfer
of all or substantially all of the assets of Borrower, or any compulsory share exchange whereby the Common Stock is converted
into other securities, cash or property or (E) Borrower shall authorize the voluntary or involuntary dissolution, liquidation
or winding up of the affairs of Borrower, then, in each case, Borrower shall cause to be filed at each office or agency maintained
for the purpose of conversion of this Note, and shall cause to be delivered to the Holder at its last address as it shall appear
upon the Note Register, at least twenty (20) calendar days prior to the applicable record or effective date hereinafter specified,
a notice stating (x) the date on which a record is to be taken for the purpose of such dividend, distribution, redemption, rights
or warrants, or if a record is not to be taken, the date as of which the holders of the Common Stock of record to be entitled
to such dividend, distributions, redemption, rights or warrants are to be determined or (y) the date on which such reclassification,
consolidation, merger, sale, transfer or share exchange is expected to become effective or close, and the date as of which it
is expected that holders of the Common Stock of record shall be entitled to exchange their shares of the Common Stock for securities,
cash or other property deliverable upon such reclassification, consolidation, merger, sale, transfer or share exchange, provided
that the failure to deliver such notice or any defect therein or in the delivery thereof shall not affect the validity of the
corporate action required to be specified in such notice. To the extent that any notice provided hereunder constitutes, or contains,
material, non-public information regarding Borrower or any of the Subsidiaries, Borrower shall simultaneously file such notice
with the TSX Venture Exchange. The Holder shall remain entitled to convert this Note during the 20-day period commencing on the
date of such notice through the effective date of the event triggering such notice except as may otherwise be expressly set forth
herein.

 

    	 	13	 

    	 

    

 

Section
6. Intentionally omitted.

 

Section
7. Negative Covenants. As long as any principal amount of this Note and the Other Notes remains outstanding, unless
the holders of at least 51% in principal amount of the then outstanding Notes shall have otherwise given prior written consent,
Borrower shall not, and shall not permit any of the Subsidiaries to, directly or indirectly:

 

a)
other than Permitted Indebtedness, enter into, create, incur, assume, guarantee or suffer to exist any indebtedness for borrowed
money of any kind, including, but not limited to, a guarantee, on or with respect to any of its property or assets now owned or
hereafter acquired or any interest therein or any income or profits therefrom;

 

b)
other than Permitted Liens, enter into, create, incur, assume or suffer to exist any Liens of any kind, on or with respect to
any of its property or assets now owned or hereafter acquired or any interest therein or any income or profits therefrom;

 

c)
amend its charter documents, including, without limitation, its certificate of incorporation and bylaws, in any manner that materially
adversely affects any rights of the Holder;

 

d)
repay, repurchase or offer to repay, repurchase or otherwise acquire more than a de minimis number of shares of its Common
Stock or Common Stock Equivalents other than as to the Conversion Shares or Warrant Shares as permitted or required under the
Transaction Documents;

 

e)
redeem, defease, repurchase, repay or make any payments in respect of, by the payment of cash or cash equivalents (in whole or
in part, whether by way of open market purchases, tender offers, private transactions or otherwise), all or any portion of any
Indebtedness (other than the Notes if on a pro-rata basis), whether by way of payment in respect of principal of (or premium,
if any) or interest on, such Indebtedness;

 

f)
declare or make any dividend or other distribution of its assets or rights to acquire its assets to holders of shares of Common
Stock, preferred stock, or any other equity security by way of return of capital or otherwise including, without limitation, any
distribution of cash, stock or other securities, property or options by way of a dividend, spin off, reclassification, corporate
rearrangement, scheme of arrangement or other similar transaction;

 

    	 	14	 

    	 

    

 

g)
sell or offer to sell any securities with non-fixed or floating price features, issued any equity or debt instrument at a price
lower than the conversion price herein then in effect, or issue any equity or debt instruments with anti-dilution provisions;
or

 

h)
enter into any agreement with respect to any of the foregoing.

 

Section
8. Events of Default.

 

a)
“Event of Default” means, wherever used herein, any of the following events (whatever the reason for such event
and whether such event shall be voluntary or involuntary or effected by operation of law or pursuant to any judgment, decree or
order of any court, or any order, rule or regulation of any administrative or governmental body):

 

i.
any default in the payment of (A) the principal or interest, if any, amount of this Note or (B) liquidated damages and other amounts
owing to a Holder on any Note, as and when the same shall become due and payable (whether on a Conversion Date or the Maturity
Date or by acceleration or otherwise) which default, solely in the case of a default under clause (B) above, is not cured within
five Trading Days after Borrower has become or should have become aware of such default;

 

ii.
Borrower shall fail to observe or perform any other covenant or agreement contained in the Notes (other than a breach by Borrower
of its obligations to deliver shares of Common Stock to the Holder upon conversion, which breach is addressed in clause (ix) below)
which failure is not cured, if possible to cure, within the earlier to occur of (A) 5 Trading Days after notice of such failure
sent by the Holder or by any Other Holder to Borrower and (B) 10 Trading Days after Borrower has become or should have become
aware of such failure;

 

iii.
a default or event of default (subject to any grace or cure period provided in the applicable agreement, document or instrument)
shall occur under (A) any of the Transaction Documents, or (B) any other material agreement, lease, document or instrument to
which Borrower or any Subsidiary is obligated (and not covered by clause (vi) below);

 

iv.
any representation or warranty made in this Note, any other Transaction Documents, any written statement pursuant hereto or thereto
or any other report, financial statement or certificate made or delivered to the Holder or any Other Holder shall be untrue or
incorrect in any material respect as of the date when made or deemed made;

 

v.
Borrower or any Subsidiary shall be subject to a Bankruptcy Event;

 

vi.
Borrower or any Subsidiary shall default on any of its obligations under any mortgage, credit agreement or other facility, indenture
agreement, factoring agreement or other instrument under which there may be issued, or by which there may be secured or evidenced,
any indebtedness for borrowed money or money due under any long term leasing or factoring arrangement that (a) involves an obligation
greater than $50,000, whether such indebtedness now exists or shall hereafter be created, and (b) results in such indebtedness
becoming or being declared due and payable prior to the date on which it would otherwise become due and payable;

 

    	 	15	 

    	 

    

 

vii.
Borrower shall have consummated any Change of Control Transaction or Fundamental Transaction without giving Holder at least ten
Trading Days prior written notice;

 

viii.
Borrower does not meet the current public information requirements under NI 45-106 or Rule 144;

 

ix.
Borrower shall fail for any reason to deliver certificates to a Holder prior to the third Trading Day after a Conversion Date
pursuant to Section 4(c) or Borrower shall provide at any time notice to the Holder, including by way of public announcement,
of Borrower’s intention to not honor requests for conversions of any Notes in accordance with the terms hereof;

 

x.
intentionally omitted;

 

xi.
any monetary judgment, writ or similar final process shall be entered or filed against Borrower, any subsidiary or any of their
respective property or other assets for more than $150,000, and such judgment, writ or similar final process shall remain unvacated,
unbonded or unstayed for a period of 60 calendar days;

 

xii.
other than as a result of a Fundamental Transaction, any dissolution, liquidation or winding up by Borrower or a material Subsidiary
of a substantial portion of their business;

 

xiii.
other than as a result of a Fundamental Transaction, cessation of operations by Borrower or a material Subsidiary;

 

xiv.
an event resulting in the Common Stock no longer being listed or quoted on a Trading Market, or notification from a Trading Market
that the Borrower is not in compliance with the conditions for such continued quotation and such non-compliance continues for
twenty (20) days following such notification;

 

xv.
a Commission, the TSX Venture Exchange, Canadian Securities Commission or judicial stop trade order or suspension from the Borrower’s
Principal Trading Market or the OTCQB;

 

xvi.
the Borrower effectuates a reverse split of its Common Stock without ten (10) days prior written notice to the Holder;

 

xvii.
a failure by Borrower to notify Holder of any material event of which Borrower is obligated to notify Holder pursuant to the terms
of this Note or any other Transaction Document;

 

xviii.
a default by the Borrower of a material term, covenant, warranty or undertaking of any other agreement to which the Borrower and
Holder are parties, or the occurrence of an event of default under any such other agreement to which Borrower and Holder are parties
which is not cured after any required notice and/or cure period;

 

xix.
the occurrence of an Event of Default under any Other Note;

 

    	 	16	 

    	 

    

 

xx.
any material provision of any Transaction Document shall at any time for any reason (other than pursuant to the express terms
thereof) cease to be valid and binding on or enforceable against the Borrower, or the validity or enforceability thereof shall
be contested by Borrower, or a proceeding shall be commenced by Borrower or any governmental authority having jurisdiction over
Borrower or Holder, seeking to establish the invalidity or unenforceability thereof, or Borrower shall deny in writing that it
has any liability or obligation purported to be created under any Transaction Document;

 

xxi.
the failure by Borrower or any material Subsidiary to maintain any material intellectual property rights, personal, real property,
equipment, leases or other assets which are necessary to conduct its business (whether now or in the future) and such breach is
not cured with twenty (20) days after written notice to the Borrower from the Holder;

 

xxii.
the restatement after the date hereof of any financial statements filed by the Borrower under any Applicable Law for any date
or period from two years prior to the Original Issue Date and until this Note is no longer outstanding, if the result of such
restatement would, by comparison to the unrestated financial statements, have constituted a Material Adverse Effect. For the avoidance
of doubt, any restatement related to new accounting pronouncements shall not constitute a default under this Section; or

 

xxiii.
the occurrence of an Event of Default as defined in and under any other debt instrument issued by Borrower to Holder or Other
Holder.

 

b)
Remedies Upon Event of Default, Fundamental Transaction and Change of Control Transaction. If any Event of Default or a
Fundamental Transaction or a Change of Control Transaction occurs, the outstanding principal amount of this Note, liquidated damages
and other amounts owing in respect thereof through the date of acceleration, shall become, at the Holder’s election, immediately
due and payable in cash at the Mandatory Default Amount. Commencing on the Maturity Date and also five (5) Trading Days after
the occurrence of any Event of Default interest on this Note shall accrue at an interest rate equal to the lesser of 15% per annum
or the maximum rate permitted under Applicable Law. Upon the payment in full of the Mandatory Default Amount, the Holder shall
promptly surrender this Note to or as directed by Borrower. In connection with such acceleration described herein, the Holder
need not provide, and Borrower hereby waives, any presentment, demand, protest or other notice of any kind, and the Holder may
immediately and without expiration of any grace period enforce any and all of its rights and remedies hereunder and all other
remedies available to it under Applicable Law. Such acceleration may be rescinded and annulled by Holder at any time prior to
payment hereunder and the Holder shall have all rights as a holder of the Note until such time, if any, as the Holder receives
full payment pursuant to this Section 8(b). No such rescission or annulment shall affect any subsequent Event of Default or impair
any right consequent thereon.

 

    	 	17	 

    	 

    

 

Section
9. Section 10. Miscellaneous.

 

a)
Notices. All notices, demands, requests, consents, approvals, and other communications required or permitted hereunder
shall be in writing and, unless otherwise specified herein, shall be (i) personally served, (ii) deposited in the mail, registered
or certified, return receipt requested, postage prepaid, (iii) delivered by reputable air courier service with charges prepaid,
or (iv) transmitted by hand delivery, telegram, or facsimile, addressed as set forth below or to such other address as such party
shall have specified most recently by written notice. Any notice or other communication required or permitted to be given hereunder
shall be deemed effective (a) upon hand delivery or delivery by facsimile, with accurate confirmation generated by the transmitting
facsimile machine, at the address or number designated below (if delivered on a Trading Day during normal business hours where
such notice is to be received), or the first Trading Day following such delivery (if delivered other than on a Trading Day during
normal business hours where such notice is to be received) or (b) on the second Trading Day following the date of mailing by express
courier service, fully prepaid, addressed to such address, or upon actual receipt of such mailing, whichever shall first occur.
The addresses for such communications shall be: (i) if to Borrower, to: BriaCell Therapeutics Corp., Inc., Suite 300 – Bellevue
Centre, 235 – 15th Street, West Vancouver, British Columbia, Canada, with a copy by fax only to Dr. William V.
Williams, Fax: 604-921-1898 and (ii) if to the Holder, to: the address and fax number indicated on the front page of this Note,
with an additional copy by fax only to (which shall not constitute notice): Grushko & Mittman, P.C., 515 Rockaway Avenue,
Valley Stream, New York 11581, facsimile: (212) 697-3575.

 

b)
Absolute Obligation. Except as expressly provided herein, no provision of this Note shall alter or impair the obligation
of Borrower, which is absolute and unconditional, to pay the principal of, liquidated damages and accrued interest, as applicable,
on this Note at the time, place, and rate, and in the coin or currency, herein prescribed. This Note is a direct debt obligation
of Borrower. This Note ranks pari passu with all other Notes now or hereafter issued under the terms set forth herein pursuant
to the Purchase Agreement.

 

c)
Lost or Mutilated Note. If this Note shall be mutilated, lost, stolen or destroyed, Borrower shall execute and deliver,
in exchange and substitution for and upon cancellation of a mutilated Note, or in lieu of or in substitution for a lost, stolen
or destroyed Note, a new Note for the principal amount of this Note so mutilated, lost, stolen or destroyed, but only upon receipt
of evidence of such loss, theft or destruction of such Note, and of the ownership hereof, reasonably satisfactory to Borrower.

 

d)
Governing Law. All questions concerning the construction, validity, enforcement and interpretation of this Note shall be
governed by and construed and enforced in accordance with the internal laws of the State of New York, without regard to the principles
of conflict of laws thereof. Each party agrees that all legal proceedings concerning the interpretation, enforcement and defense
of the transactions contemplated by any of the Transaction Documents (whether brought against a party hereto or its respective
Affiliates, directors, officers, shareholders, employees or agents) shall be commenced in the state and federal courts sitting
in the City of New York, Borough of Manhattan (the “New York Courts”). Each party hereto hereby irrevocably
submits to the exclusive jurisdiction of the New York Courts for the adjudication of any dispute hereunder or in connection herewith
or with any transaction contemplated hereby or discussed herein (including with respect to the enforcement of any of the Transaction
Documents), and hereby irrevocably waives, and agrees not to assert in any suit, action or proceeding, any claim that it is not
personally subject to the jurisdiction of such New York Courts, or such New York Courts are improper or inconvenient venue for
such proceeding. Each party hereby irrevocably waives personal service of process and consents to process being served in any
such suit, action or proceeding by mailing a copy thereof via registered or certified mail or overnight delivery (with evidence
of delivery) to such party at the address in effect for notices to it under this Note and agrees that such service shall constitute
good and sufficient service of process and notice thereof. Nothing contained herein shall be deemed to limit in any way any right
to serve process in any other manner permitted by Applicable Law. Each party hereto hereby irrevocably waives, to the fullest
extent permitted by Applicable Law, any and all right to trial by jury in any legal proceeding arising out of or relating to this
Note or the transactions contemplated hereby. If any party shall commence an action or proceeding to enforce any provisions of
this Note, then the prevailing party in such action or proceeding shall be reimbursed by the other party for its attorneys fees
and other costs and expenses incurred in the investigation, preparation and prosecution of such action or proceeding. This
Note shall be deemed an unconditional obligation of Borrower for the payment of money and, without limitation to any other remedies
of Holder, may be enforced against Borrower by summary proceeding pursuant to New York Civil Procedure Law and Rules Section 3213
or any similar rule or statute in the jurisdiction where enforcement is sought. For purposes of such rule or statute, any other
document or agreement to which Holder and Borrower are parties or which Borrower delivered to Holder, which may be convenient
or necessary to determine Holder’s rights hereunder or Borrower’s obligations to Holder are deemed a part of this
Note, whether or not such other document or agreement was delivered together herewith or was executed apart from this Note.

 

    	 	18	 

    	 

    

 

e)
Waiver. Any waiver by Borrower or the Holder of a breach of any provision of this Note shall not operate as or be construed
to be a waiver of any other breach of such provision or of any breach of any other provision of this Note. The failure of Borrower
or the Holder to insist upon strict adherence to any term of this Note on one or more occasions shall not be considered a waiver
or deprive that party of the right thereafter to insist upon strict adherence to that term or any other term of this Note on any
other occasion. Any waiver by Borrower or the Holder must be in writing.

 

f)
Severability. If any provision of this Note is invalid, illegal or unenforceable, the balance of this Note shall remain
in effect, and if any provision is inapplicable to any Person or circumstance, it shall nevertheless remain applicable to all
other Persons and circumstances.

 

g)
Usury. If it shall be found that any interest or other amount deemed interest due hereunder violates the Applicable Law
governing usury, the applicable rate of interest due hereunder shall automatically be lowered to equal the maximum rate of interest
permitted under Applicable Law. Borrower covenants (to the extent that it may lawfully do so) that it shall not at any time insist
upon, plead, or in any manner whatsoever claim or take the benefit or advantage of, any stay, extension or usury law or other
law which would prohibit or forgive Borrower from paying all or any portion of the principal of or interest on this Note as contemplated
herein, wherever enacted, now or at any time hereafter in force, or which may affect the covenants or the performance of this
Note, and Borrower (to the extent it may lawfully do so) hereby expressly waives all benefits or advantage of any such law, and
covenants that it will not, by resort to any such law, hinder, delay or impede the execution of any power herein granted to the
Holder, but will suffer and permit the execution of every such as though no such law has been enacted.

 

h)
Next Trading Day. Whenever any payment or other obligation hereunder shall be due on a day other than a Trading Day, such
payment shall be made on the next succeeding Trading Day.

 

i)
Headings; Dollar Amounts. The headings contained herein are for convenience only, do not constitute a part of this Note
and shall not be deemed to limit or affect any of the provisions hereof. Unless otherwise specified herein, all dollar amounts
are in CDN$.

 

j)
Amendment. Unless otherwise provided for hereunder, this Note may not be modified or amended or the provisions hereof waived
without the written consent of Borrower and the Holder.

 

k)
Facsimile Signature. In the event that the Borrower’s signature is delivered by facsimile transmission, PDF, electronic
signature or other similar electronic means, such signature shall create a valid and binding obligation of the Borrower with the
same force and effect as if such signature page were an original thereof.

 

*********************

 

(Signature
Pages Follow)

 

    	 	19	 

    	 

    

 

IN
WITNESS WHEREOF, Borrower has caused this Note to be signed in its name by an authorized officer as of the ____ day of March,
2018.

 

	 	 	BRIACELL
    THERAPEUTICS CORP.
	 	 	 	 
	 	 	By:	 
	 	 	Name:	                    
	 	 	Title:	 
	 	 	 	 
	WITNESS:	 	 	 
	 	 	 	 
	 	 	 	 

 

    	 	20	 

    	 

    

 

ANNEX
A

 

NOTICE
OF CONVERSION

 

The
undersigned hereby elects to convert principal under the Convertible Note Due August __, 2018 of BriaCell Therapeutics Corp.,
a British Columbia corporation (the “Company”), into shares of common stock (the “Common Stock”),
of Borrower according to the conditions hereof, as of the date written below. If shares of Common Stock are to be issued in the
name of a person other than the undersigned, the undersigned will pay all transfer taxes payable with respect thereto and is delivering
herewith such certificates and opinions as reasonably requested by Borrower in accordance therewith. No fee will be charged to
the holder for any conversion, except for such transfer taxes, if any.

 

By
the delivery of this Notice of Conversion the undersigned represents and warrants to Borrower that its ownership of the Common
Stock does not exceed the amounts specified under Section 4 of this Note, as determined in accordance with Section 13(d) of the
Exchange Act.

 

The
undersigned agrees to comply with the prospectus delivery requirements under the Applicable Law in connection with any transfer
of the aforesaid shares of Common Stock.

 

Conversion
calculations:

	 	Date
    to Effect Conversion: ____________________________
	 	 
	 	Principal
    Amount of Note to be Converted: $__________________
	 	 
	 	Applicable
        Conversion Price: $__________________

         

        Interest
        Amount to be Converted: $_________________________

         

        Applicable
        Conversion Price: $___________________________

         

        Number
        of shares of Common Stock to be issued: ______________

	 	 
	 	Signature:
    _________________________________________
	 	 
	 	Name:
    ____________________________________________
	 	 
	 	Address
    for Delivery of Common Stock Certificates: __________
	 	_____________________________________________________
    
	 	_____________________________________________________
	 	 
	 	Or
	 	 
	 	DWAC
    Instructions: _________________________________
	 	 
	 	Broker
    No:_____________
	 	Account
    No: _______________

 

    	 	21Exhibit 10.34 

 

UNLESS
PERMITTED UNDER SECURITIES LEGISLATION, THE HOLDER OF THIS SECURITY MUST NOT TRADE THE SECURITY BEFORE JULY 17, 2018

 

WITHOUT
PRIOR WRITTEN APPROVAL OF THE TSX VENTURE EXCHANGE AND COMPLIANCE WITH ALL APPLICABLE SECURITIES LEGISLATION, THE SECURITIES REPRESENTED
BY OR UNDERLYING THIS CERTIFICATE MAY NOT BE SOLD, TRANSFERRED, HYPOTHECATED OR OTHERWISE TRADED ON OR THROUGH THE FACILITIES
OF THE TSX VENTURE EXCHANGE OR OTHERWISE IN CANADA OR TO OR FOR THE BENEFIT OF A CANADIAN RESIDENT UNTIL JULY 17, 2018.

 

THE
SECURITIES REPRESENTED HEREBY AND THE SECURITIES ISSUABLE UPON EXERCISE HEREOF HAVE NOT BEEN AND WILL NOT BE REGISTERED UNDER
THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED (THE “U.S. SECURITIES ACT”), OR THE LAWS OF ANY STATE OF THE
UNITED STATES. THE HOLDER HEREOF, BY PURCHASING SUCH SECURITIES, AGREES FOR THE BENEFIT OF THE CORPORATION THAT SUCH SECURITIES
MAY BE OFFERED, SOLD, PLEDGED OR OTHERWISE TRANSFERRED ONLY (A) TO THE CORPORATION, (B) OUTSIDE THE UNITED STATES IN ACCORDANCE
WITH RULE 904 OF REGULATION S UNDER THE U.S. SECURITIES ACT AND IN COMPLIANCE WITH APPLICABLE LOCAL LAWS AND REGULATIONS, (C)
IN COMPLIANCE WITH THE EXEMPTION FROM REGISTRATION UNDER THE U.S. SECURITIES ACT PROVIDED BY (1) RULE 144 THEREUNDER, IF AVAILABLE,
OR (2) RULE 144A THEREUNDER, IF AVAILABLE, AND, IN BOTH CASES, IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS OR (D) IN ANOTHER
TRANSACTION THAT DOES NOT REQUIRE REGISTRATION UNDER THE U.S. SECURITIES ACT OR ANY APPLICABLE STATE SECURITIES LAWS AND, IN THE
CASE OF (C)(1) AND (D) ABOVE, AFTER THE SELLER FURNISHES TO THE CORPORATION AN OPINION OF COUNSEL OF RECOGNIZED STANDING OR SUCH
OTHER EVIDENCE IN FORM AND SUBSTANCE REASONABLY SATISFACTORY TO THE CORPORATION TO SUCH EFFECT. DELIVERY OF THIS CERTIFICATE MAY
NOT CONSTITUTE “GOOD DELIVERY” IN SETTLEMENT OF TRANSACTIONS ON STOCK EXCHANGES IN CANADA. A NEW CERTIFICATE BEARING
NO LEGEND, DELIVERY OF WHICH WILL CONSTITUTE “GOOD DELIVERY”, MAY BE OBTAINED FROM THE TRANSFER AGENT AND REGISTRAR
OF THE CORPORATION UPON DELIVERY OF THIS CERTIFICATE AND A DULY EXECUTED DECLARATION, IN A FORM SATISFACTORY TO THE TRANSFER AGENT
AND REGISTRAR OF THE CORPORATION AND THE CORPORATION, TO THE EFFECT THAT THE SALE OF THE SECURITIES REPRESENTED HEREBY IS BEING
MADE IN COMPLIANCE WITH RULE 904 OF REGULATION S UNDER THE U.S. SECURITIES ACT.

 

WARRANTS
TO PURCHASE

COMMON SHARES OF BRIACELL THERAPEUTICS CORP.

 

	Warrant
                                         Certificate Number:

                                                                      

        2018
        March – US 001
	Number
                                         of Warrants:

                                                                      

        [●]

 

THIS
IS TO CERTIFY THAT for value received by [●] at [●] (the “Warrantholder”) has the right
to purchase in respect of each whole warrant (individually, a “Warrant” and, collectively, the “Warrants”)
represented by this certificate or by a replacement certificate (in either case, this “Warrant Certificate”),
at any time up to 5:00 p.m. Toronto time, on March 16, 2021 (the “Expiry Time”), one fully paid and non-assessable
common share (individually, a “Common Share” and, collectively, the “Common Shares” and
which terms shall include any shares or other securities to be issued in addition thereto or in substitution or replacement therefor
as provided herein) of BriaCell Therapeutics Corp. (the “Corporation”), a corporation existing under the Business
Corporations Act (British Columbia), as constituted on the date hereof at a purchase price (the purchase price in effect from
time to time being called the “Exercise Price”) of $0.14 per Common Share, subject to adjustment as provided
herein.

 

    	 

    	 

    

 

The
Corporation agrees that the Common Shares purchased pursuant to the exercise of the Warrants shall be and be deemed to be issued
to the Warrantholder as of the close of business on the date on which this Warrant Certificate shall have been surrendered and
payment made for such Common Shares as aforesaid.

 

Nothing
contained herein shall confer any right upon the Warrantholder to subscribe for or purchase any Common Shares at any time after
the Expiry Time and from and after the Expiry Time the Warrants and all rights under this Warrant Certificate shall be void and
of no value.

 

The
above provisions are subject to the following:

 

	1.	Exercise:
    In the event that the Warrantholder desires to exercise the right to purchase Common Shares conferred hereby, the
    Warrantholder shall (a) complete, to the extent possible in the manner indicated, and execute a subscription form in the form
    attached as Schedule A to this Warrant Certificate, (b) surrender this Warrant Certificate to the Corporation in accordance
    with section 9 of this Warrant Certificate, and (c) pay the amount payable upon the exercise of such Warrants in respect of
    the Common Shares subscribed for by certified cheque, bank draft or money order in lawful money of Canada payable to the Corporation
    or by transmitting same day funds in lawful money of Canada by wire to such account as the Corporation shall direct the Warrantholder.
    Upon such surrender and payment as aforesaid, the Warrantholder shall be deemed for all purposes to be the holder of record
    of the number of Common Shares to be so issued and the Warrantholder shall be entitled to delivery of a certificate or certificates
    representing such Common Shares and the Corporation shall cause such certificate or certificates to be delivered to the Warrantholder
    at the address specified in the subscription form within three business days after such surrender and payment as aforesaid.
    No fractional Common Shares will be issuable upon any exercise of the Warrants and the Warrantholder will not be entitled
    to any cash payment or compensation in lieu of a fractional Common Share.
	 	 
	2.	Partial
    Exercise: The Warrantholder may from time to time subscribe for and purchase any lesser number of Common Shares than
    the number of Common Shares expressed in this Warrant Certificate. In the event that the Warrantholder subscribes for and
    purchases any such lesser number of Common Shares prior to the Expiry Time, the Warrantholder shall be entitled to receive
    a replacement certificate representing the unexercised balance of the Warrants.
	 	 
	3.	Not
    a Shareholder: The holding of the Warrants shall not constitute the Warrantholder a shareholder of the Corporation
    nor entitle the Warrantholder to any right or interest in respect thereof except as expressly provided in this Warrant Certificate.
	 	 
	4.	Covenants,
    Representations and Warranties: The Corporation hereby represents and warrants that it is authorized to create and
    issue the Warrants and covenants and agrees that it will cause the Common Shares from time to time subscribed for and purchased
    in the manner provided in this Warrant Certificate and the certificate or certificates representing such Common Shares to
    be issued and that, at all times prior to the Expiry Time, it will reserve and there will remain unissued a sufficient number
    of Common Shares to satisfy the right of purchase provided for in this Warrant Certificate. The Corporation hereby further
    covenants and agrees that it will, at its expense, expeditiously use its best efforts to obtain the listing of such Common
    Shares (subject to issue or notice of issue) on each stock exchange or over-the-counter market on which the Common Shares
    may be listed from time to time. All Common Shares which are issued upon the exercise of the right of purchase provided in
    this Warrant Certificate, upon payment therefor of the amount at which such Common Shares may be purchased pursuant to the
    provisions of this Warrant Certificate, shall be deemed to be fully paid and non-assessable shares and free from all taxes,
    liens and charges with respect to the issue thereof. The Corporation hereby represents and warrants that this Warrant Certificate
    is a valid and enforceable obligation of the Corporation, enforceable in accordance with the provisions of this Warrant Certificate.

 

    	2

    	 

    

 

	5.	Anti-Dilution
    Protection:

 

	 	(1)	Definitions:
    For the purposes of this section 5, unless there is something in the subject matter or context inconsistent therewith, the
    words and terms defined below shall have the respective meanings specified therefor in this subsection 5(1):

 

	 	(a)	“Adjustment
    Period” means the period commencing on the date of issue of the Warrants and ending at the Expiry Time;
	 	 	 
	 	(b)	“Current
    Market Price” of the Common Shares at any date means the price per share equal to the weighted average price at
    which the Common Shares have traded on the TSX Venture Exchange or, if the Common Shares are not then listed on the TSX Venture
    Exchange, on such other Canadian stock exchange as may be selected by the directors of the Corporation for such purpose or,
    if the Common Shares are not then listed on any Canadian stock exchange, in the over-the-counter market, during the period
    of any 20 consecutive trading days ending on the third business day before such date; provided that the weighted average price
    shall be determined by dividing the aggregate sale price of all Common Shares sold on the said exchange or market, as the
    case may be, during such 20 consecutive trading days by the total number of Common Shares so sold; and provided further that
    if the Common Shares are not then listed on any Canadian stock exchange or traded in the over-the-counter market, then the
    Current Market Price shall be determined by a firm of independent chartered accountants selected by the directors of the Corporation;
	 	 	 
	 	(c)	“director”
    or “director of the Corporation” means a director of the Corporation for the time being and, unless otherwise
    specified herein, a reference to action “by the directors” means action by the directors of the Corporation as
    a board or, whenever empowered, action by any committee of the directors of the Corporation; and
	 	 	 
	 	(d)	“trading
    day” with respect to a stock exchange or over-the-counter market means a day on which such stock exchange or market
    is open for business.

 

    	3

    	 

    

 

	 	(2)	Adjustments:
    The Exercise Price and the number of Common Shares issuable to the Warrantholder pursuant to this Warrant Certificate shall
    be subject to adjustment from time to time in the events and in the manner provided as follows:

 

	 	(a)	If,
    at any time during the Adjustment Period, the Corporation shall:

 

	 	(i)	fix
    a record date for the issue of, or issue, Common Shares to the holders of all or substantially all of the outstanding Common
    Shares by way of a stock dividend;
	 	 	 
	 	(ii)	fix
    a record date for the distribution to, or make a distribution to, the holders of all or substantially all of the outstanding
    Common Shares payable in Common Shares or securities exchangeable or exercisable for or convertible into Common Shares;
	 	 	 
	 	(iii)	subdivide
    the outstanding Common Shares into a greater number of Common Shares; or
	 	 	 
	 	(iv)	consolidate
    the outstanding Common Shares into a lesser number of Common Shares

 

(any
of such events in subclauses 5(2)(a)(i), 5(2)(a)(ii), 5(2)(a)(iii) and 5(2)(a)(iv) above being herein called a “Common
Share Reorganization”), the Exercise Price shall be adjusted on the earlier of the record date on which holders of Common
Shares are determined for the purposes of the Common Share Reorganization and the effective date of the Common Share Reorganization
to the amount determined by multiplying the Exercise Price in effect immediately prior to such record date or effective date,
as the case may be, by a fraction:

 

	 	A.	the
    numerator of which shall be the number of Common Shares outstanding on such record date or effective date, as the case may
    be, before giving effect to such Common Share Reorganization; and
	 	 	 
	 	B.	the
    denominator of which shall be the number of Common Shares which will be outstanding immediately after giving effect to such
    Common Share Reorganization (including, in the case of a distribution of securities exchangeable or exercisable for or convertible
    into Common Shares, the number of Common Shares that would have been outstanding had such securities been exchanged or exercised
    for or converted into Common Shares on such date).

 

To
the extent that any adjustment in the Exercise Price occurs pursuant to this clause 5(2)(a) as a result of the fixing by the Corporation
of a record date for the distribution of securities exchangeable or exercisable for or convertible into Common Shares, the Exercise
Price shall be readjusted immediately after the expiry of any relevant exchange, exercise or conversion right to the Exercise
Price which would then be in effect based upon the number of Common Shares actually issued and remaining issuable after such expiry
and shall be further readjusted in such manner upon the expiry of any further such right. Any Warrantholder who has not exercised
his right to subscribe for and purchase Common Shares on or prior to the record date of such stock dividend or distribution or
the effective date of such subdivision or consolidation, as the case may be, upon the exercise of such right thereafter shall
be entitled to receive and shall accept in lieu of the number of Common Shares then subscribed for and purchased by such Warrantholder,
at the Exercise Price determined in accordance with this clause 5(2)(a), the aggregate number of Common Shares that such Warrantholder
would have been entitled to receive as a result of such Common Share Reorganization, if, on such record date or effective date,
as the case may be, such Warrantholder had been the holder of record of the number of Common Shares so subscribed for and purchased.

 

    	4

    	 

    

 

	 	(b)	If,
    at any time during the Adjustment Period, the Corporation shall fix a record date for the issue or distribution to the holders
    of all or substantially all of the outstanding Common Shares of rights, options or warrants pursuant to which such holders
    are entitled, during a period expiring not more than 45 days after the record date for such issue (such period being the “Rights
    Period”), to subscribe for or purchase Common Shares or securities exchangeable or exercisable for or convertible
    into Common Shares at a price per share to the holder (or, in the case of securities exchangeable or exercisable for or convertible
    into Common Shares, at an exchange, exercise or conversion price per share) at the date of issue of such securities of less
    than 95% of the Current Market Price of the Common Shares on such record date (any of such events being called a “Rights
    Offering”), the Exercise Price shall be adjusted effective immediately after the record date for such Rights Offering
    to the amount determined by multiplying the Exercise Price in effect on such record date by a fraction:

 

	 	(i)	the
    numerator of which shall be the aggregate of

 

	 	A.	the
    number of Common Shares outstanding on the record date for the Rights Offering, and
	 	 	 
	 	B.	the
    quotient determined by dividing

 

	 	(1)	either
    (a) the product of the number of Common Shares offered during the Rights Period pursuant to the Rights Offering and the price
    at which such Common Shares are offered, or, (b) the product of the exchange, exercise or conversion price of the securities
    so offered and the number of Common Shares for or into which the securities offered pursuant to the Rights Offering may be
    exchanged, exercised or converted, as the case may be, by
	 	 	 
	 	(2)	the
    Current Market Price of the Common Shares as of the record date for the Rights Offering; and

 

	 	(ii)	the
    denominator of which shall be the aggregate of the number of Common Shares outstanding on such record date and the number
    of Common Shares offered pursuant to the Rights Offering (including, in the case of the issue or distribution of securities
    exchangeable or exercisable for or convertible into Common Shares, the number of Common Shares for or into which such securities
    may be exchanged, exercised or converted).

 

    	5

    	 

    

 

If,
by the terms of the rights, options or warrants referred to in this clause 5(2)(b), there is more than one purchase, exchange,
exercise or conversion price per Common Share, the aggregate price of the total number of additional Common Shares offered for
subscription or purchase, or the aggregate exchange, exercise or conversion price of the exchangeable, exercisable or convertible
securities so offered, shall be calculated for purposes of the adjustment on the basis of the lowest purchase, exchange, exercise
or conversion price per Common Share, as the case may be. Any Common Shares owned by or held for the account of the Corporation
shall be deemed not to be outstanding for the purpose of any such calculation. To the extent that any adjustment in the Exercise
Price occurs pursuant to this clause 5(2)(b) as a result of the fixing by the Corporation of a record date for the issue or distribution
of rights, options or warrants referred to in this clause 5(2)(b), the Exercise Price shall be readjusted immediately after the
expiry of any relevant exchange, exercise or conversion right to the Exercise Price which would then be in effect based upon the
number of Common Shares actually issued and remaining issuable after such expiry and shall be further readjusted in such manner
upon the expiry of any further such right.

 

	 	(c)	If,
    at any time during the Adjustment Period, the Corporation shall fix a record date for the issue or distribution to the holders
    of all or substantially all of the outstanding Common Shares of:

 

	 	(i)	shares
    of the Corporation of any class other than Common Shares;
	 	 	 
	 	(ii)	rights,
    options or warrants to acquire Common Shares or securities exchangeable or exercisable for or convertible into Common Shares
    (other than rights, options or warrants pursuant to which holders of Common Shares are entitled, during a period expiring
    not more than 45 days after the record date for such issue, to subscribe for or purchase Common Shares or securities exchangeable
    or exercisable for or convertible into Common Shares at a price per share (or, in the case of securities exchangeable or exercisable
    for or convertible into Common Shares, at an exchange, exercise or conversion price per share) of at least 95% of the Current
    Market Price of the Common Shares on such record date);
	 	 	 
	 	(iii)	evidences
    of indebtedness of the Corporation; or
	 	 	 
	 	(iv)	any
    property or assets of the Corporation;

 

and
if such issue or distribution does not constitute a Common Share Reorganization or a Rights Offering (any of such non-excluded
events being herein called a “Special Distribution”), the Exercise Price shall be adjusted effective immediately
after the record date for the Special Distribution to the amount determined by multiplying the Exercise Price in effect on the
record date for the Special Distribution by a fraction:

 

		A.	the
                                         numerator of which shall be the difference between

 

    	6

    	 

    

 

	 	(1)	the
    product of the number of Common Shares outstanding on such record date and the Current Market Price of the Common Shares on
    such record date, and
	 	 	 
	 	(2)	the
    fair value, as determined by the directors of the Corporation, to the holders of Common Shares of the shares, rights, options,
    warrants, evidences of indebtedness or property or assets to be issued or distributed in the Special Distribution, and

 

	 	B.	the
    denominator of which shall be the product obtained by multiplying the number of Common Shares outstanding on such record date
    by the Current Market Price of the Common Shares on such record date.

 

Any
Common Shares owned by or held for the account of the Corporation shall be deemed not to be outstanding for the purpose of such
calculation. To the extent that any adjustment in the Exercise Price occurs pursuant to this clause 5(2)(c) as a result of the
fixing by the Corporation of a record date for the issue or distribution of rights, options or warrants to acquire Common Shares
or securities exchangeable or exercisable for or convertible into Common Shares referred to in this clause 5(2)(c), the Exercise
Price shall be readjusted immediately after the expiry of any relevant exchange, exercise or conversion right to the amount which
would then be in effect based upon the number of Common Shares issued and remaining issuable after such expiry and shall be further
readjusted in such manner upon the expiry of any further such right.

 

	 	(d)	If,
    at any time during the Adjustment Period, there shall occur:

 

	 	(i)	a
    reclassification or redesignation of the Common Shares, a change of the Common Shares into other shares or securities or any
    other capital reorganization involving the Common Shares other than a Common Share Reorganization;
	 	 	 
	 	(ii)	a
    consolidation, amalgamation, arrangement or merger of the Corporation with or into another body corporate which results in
    a reclassification or redesignation of the Common Shares or a change of the Common Shares into other shares or securities;
	 	 	 
	 	(iii)	the
    transfer of the undertaking or assets of the Corporation as an entirety or substantially as an entirety to another corporation
    or entity;

 

(any
of such events being called a “Capital Reorganization”), after the effective date of the Capital Reorganization,
the Warrantholder shall be entitled to receive, and shall accept, for the same aggregate consideration, upon exercise of the Warrants,
in lieu of the number of Common Shares to which the Warrantholder was theretofor entitled upon the exercise of the Warrants, the
kind and aggregate number of shares and other securities or property resulting from the Capital Reorganization which the Warrantholder
would have been entitled to receive as a result of the Capital Reorganization if, on the effective date thereof, the Warrantholder
had been the registered holder of the number of Common Shares which the Warrantholder was theretofore entitled to purchase or
receive upon the exercise of the Warrants. If necessary, as a result of any such Capital Reorganization, appropriate adjustments
shall be made in the application of the provisions of this Warrant Certificate with respect to the rights and interests thereafter
of the Warrantholder to the end that the provisions shall thereafter correspondingly be made applicable as nearly as may reasonably
be possible in relation to any shares or other securities or property thereafter deliverable upon the exercise of the Warrants.

 

    	7

    	 

    

 

	 	(e)	If,
    at any time during the Adjustment Period, any adjustment or readjustment in the Exercise Price shall occur pursuant to the
    provisions of clause 5(2)(a), 5(2)(b) or 5(2)(c) of this Warrant Certificate, then the number of Common Shares purchasable
    upon the subsequent exercise of the Warrants shall be simultaneously adjusted or readjusted, as the case may be, by multiplying
    the number of Common Shares purchasable upon the exercise of the Warrants immediately prior to such adjustment or readjustment
    by a fraction which shall be the reciprocal of the fraction used in the adjustment or readjustment of the Exercise Price.

 

	(3)	Rules:
    The following rules and procedures shall be applicable to adjustments made pursuant to subsection 5(2) of this Warrant Certificate:

 

	 	(a)	Subject
    to the following clauses of this subsection 5(3), any adjustment made pursuant to subsection 5(2) hereof shall be made successively
    whenever an event referred to therein shall occur.
	 	 	 
	 	(b)	No
    adjustment in the Exercise Price shall be required unless such adjustment would result in a change of at least one per cent
    in the then Exercise Price and no adjustment shall be made in the number of Common Shares purchasable upon the exercise of
    the Warrants unless it would result in a change of at least one one-hundredth of a Common Share; provided, however, that any
    adjustments which, except for the provision of this clause 5(3)(b), would otherwise have been required to be made shall be
    carried forward and taken into account in any subsequent adjustment. Notwithstanding any other provision of subsection 5(2)
    hereof, no adjustment of the Exercise Price shall be made which would result in an increase in the Exercise Price or a decrease
    in the number of Common Shares issuable upon the exercise of the Warrants (except in respect of the Common Share Reorganization
    described in subclause 5(2)(a)(iv) hereof or a Capital Reorganization described in subclause 5(2)(d)(ii) hereof).
	 	 	 
	 	(c)	No
    adjustment in the Exercise Price or in the number or kind of securities purchasable upon the exercise of the Warrants shall
    be made in respect of any event described in section 5 hereof if the Warrantholder is entitled to participate in such event
    on the same terms mutatis mutandis as if the Warrantholder had exercised the Warrants prior to or on the record date
    or effective date, as the case may be, of such event.
	 	 	 
	 	(d)	No
    adjustment in the Exercise Price or in the number of Common Shares purchasable upon the exercise of the Warrants shall be
    made pursuant to subsection 5(2) hereof in respect of the issue from time to time of Common Shares pursuant to this Warrant
    Certificate or pursuant to any stock option, stock purchase or stock bonus plan in effect from time to time for directors,
    officers or employees of the Corporation and/or any subsidiary of the Corporation and any such issue, and any grant of options
    in connection therewith, shall be deemed not to be a Common Share Reorganization, a Rights Offering nor any other event described
    in subsection 5(2) hereof.

 

    	8

    	 

    

 

	 	(e)	If,
    at any time during the Adjustment Period, the Corporation shall take any action affecting the Common Shares, other than an
    action or event described in subsection 5(2) hereof, which, in the opinion of the directors of the Corporation, would have
    a material adverse effect upon the rights of Warrantholders, either or both the Exercise Price and the number of Common Shares
    purchasable upon exercise of the Warrants shall be adjusted in such manner and at such time by action by the directors of
    the Corporation, in their sole discretion, as may be equitable in the circumstances. Failure of the taking of action by the
    directors of the Corporation so as to provide for an adjustment prior to the effective date of any action by the Corporation
    affecting the Common Shares shall be deemed to be conclusive evidence that the directors of the Corporation have determined
    that it is equitable to make no adjustment in the circumstances.
	 	 	 
	 	(f)	If
    the Corporation shall set a record date to determine holders of Common Shares for the purpose of entitling such holders to
    receive any dividend or distribution or any subscription or purchase rights and shall, thereafter and before the distribution
    to such holders of any such dividend, distribution or subscription or purchase rights, legally abandon its plan to pay or
    deliver such dividend, distribution or subscription or purchase rights, then no adjustment in the Exercise Price or the number
    of Common Shares purchasable upon the exercise of the Warrants shall be required by reason of the setting of such record date.
	 	 	 
	 	(g)	In
    any case in which this Warrant Certificate shall require that an adjustment shall become effective immediately after a record
    date for an event referred to in subsection 5(2) hereof, the Corporation may defer, until the occurrence of such event:

 

	 	(i)	issuing
    to the Warrantholder, to the extent that the Warrants are exercised after such record date and before the occurrence of such
    event, the additional Common Shares or other securities issuable upon such exercise by reason of the adjustment required by
    such event; and
	 	 	 
	 	(ii)	delivering
    to the Warrantholder any distribution declared with respect to such additional Common Shares or other securities after such
    record date and before such event;

 

provided,
however, that the Corporation shall deliver to the Warrantholder an appropriate instrument evidencing the right of the Warrantholder
upon the occurrence of the event requiring the adjustment, to an adjustment in the Exercise Price or the number of Common Shares
purchasable upon the exercise of the Warrants and to such distribution declared with respect to any such additional Common Shares
issuable upon the exercise of the Warrants.

 

    	9

    	 

    

 

	 	(h)	In
    the absence of a resolution of the directors of the Corporation fixing a record date for a Rights Offering, the Corporation
    shall be deemed to have fixed as the record date therefor the date of the issue of the rights, options or warrants issued
    pursuant to the Rights Offering.
	 	 	 
	 	(i)	If
    a dispute shall at any time arise with respect to adjustments of the Exercise Price or the number of Common Shares purchasable
    upon the exercise of the Warrants, such disputes shall be conclusively determined by the auditors of the Corporation or if
    they are unable or unwilling to act, by such other firm of independent chartered accountants as may be selected by the directors
    of the Corporation and any such determination shall be conclusive evidence of the correctness of any adjustment made pursuant
    to subsection 5(2) hereof and shall be binding upon the Corporation and the Warrantholder.
	 	 	 
	 	(j)	As
    a condition precedent to the taking of any action which would require an adjustment pursuant to subsection 5(2) hereof, including
    the Exercise Price and the number or class of Common Shares or other securities which are to be received upon the exercise
    thereof, the Corporation shall take any action which may, in the opinion of counsel to the Corporation, be necessary in order
    that the Corporation may validly and legally issue as fully paid and non-assessable shares all of the Common Shares or other
    securities which the Warrantholder is entitled to receive in accordance with the provisions of this Warrant Certificate.

 

	 	(4)	Notice:
    At least 21 days prior to the earlier of the record date or effective date of any event which requires or might require an
    adjustment in any of the rights of the Warrantholder under this Warrant Certificate, including the Exercise Price or the number
    of Common Shares which may be purchased under this Warrant Certificate, the Corporation shall deliver to the Warrantholder
    a certificate of the Corporation specifying the particulars of such event and, if determinable, the required adjustment and
    the calculation of such adjustment. In case any adjustment for which a notice in this subsection 5(4) has been given is not
    then determinable, the Corporation shall promptly after such adjustment is determinable deliver to the Warrantholder a certificate
    providing the calculation of such adjustment. The Corporation hereby covenants and agrees that the register of transfers and
    share transfer books for the Common Shares will be open, and that the Corporation will not take any action which might deprive
    the Warrantholder of the opportunity of exercising the rights of subscription contained in this Warrant Certificate, during
    such 21 day period.

 

	6.	Further
    Assurances: The Corporation hereby covenants and agrees that it will do, execute, acknowledge and deliver, or cause
    to be done, executed, acknowledged and delivered, all and every such other act, deed and assurance as the Warrantholder shall
    reasonably require for the better accomplishing and effectuating of the intentions and provisions of this Warrant Certificate.
	 	 
	7.	Time
    of Essence: Time shall be of the essence of this Warrant Certificate.
	 	 
	8.	Governing
    Laws: This Warrant Certificate shall be construed in accordance with the laws of the Province of British Columbia
    and the federal laws of Canada applicable therein.

 

    	10

    	 

    

 

	9.	Notices:
    All notices or other communications to be given under this Warrant Certificate shall be delivered by hand or by facsimile
    and, if delivered by hand, shall be deemed to have been given on the delivery date and, if sent by facsimile, on the date
    of transmission if sent before 5:00 p.m., Toronto time, on a business day or, if sent after 5:00 p.m., Toronto time, or such
    day is not a business day, on the first business day following the date of transmission.

 

Notices
to the Corporation shall be addressed to:

 

BriaCell
Therapeutics Corp.

3rd
Floor Bellevue Center

235-15th
Street

West
Vancouver, British Columbia V7T 2X1

Canada

 

Attention:
Dr. William Williams

Email: williams@briacell.com

 

with
a copy (which shall not constitute notice) to:

 

Bennett
Jones LLP

3400
One First Canadian Place

P.O.
Box 130

Toronto,
Ontario, M5X 1A4

Attention: Aaron Sonshine, Partner

Email:
sonshinea@bennettjones.com

 

Notices
to the Warrantholder shall be addressed to the address of the Warrantholder set out on the face page of this Warrant Certificate.

 

The
Corporation and the Warrantholder may change its address for service by notice in writing to the other of them specifying its
new address for service under this Warrant Certificate.

 

	10.	Legends
    on Common Shares: Any certificate representing Common Shares issued upon the exercise of the Warrants prior to the
    date which is four months and one day after the date hereof will bear the following legends:

 

“UNLESS
PERMITTED UNDER SECURITIES LEGISLATION, THE HOLDER OF THIS SECURITY MUST NOT TRADE THE SECURITY BEFORE JULY 17, 2018.”

 

and

 

“WITHOUT
PRIOR WRITTEN APPROVAL OF THE TSX VENTURE EXCHANGE AND COMPLIANCE WITH ALL APPLICABLE SECURITIES LEGISLATION, THE SECURITIES REPRESENTED
BY THIS CERTIFICATE MAY NOT BE SOLD, TRANSFERRED, HYPOTHECATED OR OTHERWISE TRADED ON OR THROUGH THE FACILITIES OF THE TSX VENTURE
EXCHANGE OR OTHERWISE IN CANADA OR TO OR FOR THE BENEFIT OF A CANADIAN RESIDENT UNTIL JULY 17, 2018.”;

 

provided
that at any time subsequent to the date which is four months and one day after the date hereof any certificate representing such
Common Shares may be exchanged for a certificate or certificates bearing no such legends. The Corporation hereby covenants and
agrees that it will use the best efforts thereof to deliver or to cause to be delivered a certificate or certificates representing
such Common Shares bearing no such legends within three business days after receipt of the legended certificate or certificates.

 

    	11

    	 

    

 

	11.	United
    States Restrictions on Exercise and Resale: The Warrantholder hereby acknowledges that the Warrants and the Common Shares
    issuable upon the exercise of the Warrants have not been and will not be registered under the U.S. Securities Act, or the
    securities laws of any state of the United States, and that the Warrants may not be exercised in the United States or by or
    on behalf of a “U.S. person”, as defined in Regulation S under the U.S. Securities Act, nor may the Common Shares
    issuable upon the exercise of the Warrants be offered or sold in the United States, unless an exemption is available from
    the registration requirements of the U.S. Securities Act and applicable state securities laws. If the Common Shares are being
    sold outside the United States in compliance with the requirements of Rule 904 of Regulation S, the U.S. restrictive legend
    may be removed by providing an executed declaration to the registrar and transfer agent of the Corporation, in substantially
    the form set forth as Appendix A attached hereto (or in such other forms as the Issuer may prescribe from time to time) and,
    if requested by the Issuer or the transfer agent, an opinion of counsel of recognized standing in form and substance satisfactory
    to the Corproation. If the Common Shares are offered and sold in the United States pursuant to an exemption from registration
    under the U.S. Securities Act, the Warrantholder must furnish an opinion of counsel of recognized standing in form and substance
    satisfactory to the Corporation to such effect, as applicable.
	 	 
	 	The
    Warrants represented by this Warrant Certificate may only be exercised by or on behalf of a holder who, at the time of exercise,
    can make the representations next to box 1, 2 or 3 on the Subscription Form attached hereto.
	 	 
	 	All
    certificates representing Common Shares issued to persons who exercise the Warrants pursuant to subparagraphs (2) or (3) contained
    on the Subscription Form will, unless such Common Shares are registered under the U.S. Securities Act and the securities laws
    of all applicable states of the United States bear the following legend:
	 	 
	 	“THE
    SECURITIES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED (THE “U.S.
    SECURITIES ACT”) OR UNDER ANY STATE SECURITIES LAWS. THE HOLDER HEREOF, BY PURCHASING SUCH SECURITIES, AGREES FOR THE
    BENEFIT OF THE CORPORATION THAT SUCH SECURITIES MAY BE OFFERED, SOLD OR OTHERWISE TRANSFERRED ONLY (A) TO THE CORPORATION,
    (B) OUTSIDE THE UNITED STATES IN ACCORDANCE WITH RULE 904 OF REGULATION S UNDER THE U.S. SECURITIES ACT, (C) INSIDE THE UNITED
    STATES (1) TO A QUALIFIED INSTITUTIONAL BUYER IN COMPLIANCE WITH RULE 144A UNDER THE U.S. SECURITIES ACT OR (2) PURSUANT TO
    AN EXEMPTION FROM REGISTRATION PROVIDED BY RULE 144 UNDER THE U.S. SECURITIES ACT OR ANY OTHER AVAILABLE EXEMPTION FROM THE
    REGISTRATION REQUIREMENTS OF THE U.S. SECURITIES ACT, OR (D) PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE U.S.
    SECURITIES ACT, AND IN EACH CASE IN ACCORDANCE WITH ANY APPLICABLE STATE SECURITIES LAWS IN THE UNITED STATES OR SECURITIES
    LAWS OF ANY OTHER APPLICABLE JURISDICTIONS. DELIVERY OF THIS CERTIFICATE MAY NOT CONSTITUTE “GOOD DELIVERY” IN
    SETTLEMENT OF TRANSACTIONS ON STOCK EXCHANGES IN CANADA. A NEW CERTIFICATE BEARING NO LEGEND, DELIVERY OF WHICH WILL CONSTITUTE
    “GOOD DELIVERY”, MAY BE OBTAINED FROM THE TRANSFER AGENT AND REGISTRAR OF THE CORPORATION UPON DELIVERY OF THIS
    CERTIFICATE AND A DULY EXECUTED DECLARATION, IN A FORM SATISFACTORY TO THE TRANSFER AGENT AND REGISTRAR OF THE CORPORATION
    AND THE CORPORATION, TO THE EFFECT THAT THE SALE OF THE SECURITIES REPRESENTED HEREBY IS BEING MADE IN COMPLIANCE WITH RULE
    904 OF REGULATION S UNDER THE U.S. SECURITIES ACT.”

 

    	12

    	 

    

 

provided,
that if the Common Shares are being sold outside the United States in compliance with the requirements of Rule 904 of Regulation
S, and the Issuer is at the time of such sale a “foreign issuer” within the meaning of Regulation S under the U.S.
Securities Act, the legends set forth above may be removed by providing an executed declaration to the registrar and transfer
agent of the Corporation, in substantially the form set forth as Appendix A attached hereto (or in such other forms as the Corporation
may prescribe from time to time) and, if requested by the Corporation or the transfer agent, an opinion of counsel of recognized
standing in form and substance satisfactory to the Corporation and the transfer agent to the effect that such sale is being made
in compliance with Rule 904 of Regulation S; and provided, further, that, if any Common Shares, are being sold otherwise than
in accordance with Regulation S and other than to the Corporation, the legend may be removed by delivery to the registrar and
transfer agent and the Corporation of an opinion of counsel, of recognized standing reasonably satisfactory to the Corporation,
that such legend is no longer required under applicable requirements of the U.S. Securities Act or state securities laws.

 

	12.	Lost
    Certificate: If this Warrant Certificate or any replacement hereof becomes stolen, lost, mutilated or destroyed, the
    Corporation shall, on such terms as it may in its discretion impose, acting reasonably, issue and deliver a new certificate,
    in form identical hereto but with appropriate changes, representing any unexercised portion of the subscription rights represented
    hereby to replace the certificate so stolen, lost, mutilated or destroyed.
	 	 
	13.	Transfer:
    The Warrants are transferable and the term “Warrantholder” shall mean and include any successor, transferee
    or assignee of the current or any future Warrantholder. The Warrants may be transferred by the Warrantholder completing and
    delivering to the Corporation the transfer form attached hereto as Schedule B and subject to compliance with all applicable
    laws including the applicable securities legislation and the policies of the TSX Venture Exchange.
	 	 
	14.	Successors
    and Assigns: This Warrant Certificate shall enure to the benefit of the Warrantholder and the successors and assignees
    thereof and shall be binding upon the Corporation and the successors thereof.

 

    	13

    	 

    

 

IN
WITNESS WHEREOF the Corporation has caused this Warrant Certificate to be signed by an authorized officer as of the _____
day of _______________, 2018.

 

	 	BRIACELL
    THERAPEUTICS CORP.
	 	 
	 	By:	 
	 	 	Authorized
                                         Officer

        

        

 

    	 

    	 

    

 

Schedule
A

 

	TO:	BRIACELL
    THERAPEUTICS CORP.

 

SUBSCRIPTION
FORM

 

The
undersigned hereby subscribes for _______________ common shares (“Common Shares”) of BriaCell Therapeutics
Corp. (the “Corporation”) (or such other number of Common Shares or other securities to which such subscription
entitles the undersigned in lieu thereof or in addition thereto pursuant to the provisions of the warrant certificate (the “Warrant
Certificate”) dated March 16, 2018 issued by the Corporation) at the purchase price of $0.14 per Common Share (or at
such other purchase price as may be in effect under the provisions of the Warrant Certificate) and on and subject to the other
terms and conditions specified in the Warrant Certificate and hereunder and encloses herewith a certified cheque, bank draft or
money order in lawful money of Canada payable to the Corporation or has transmitted same day funds by wire to such account as
the Corporation directed the undersigned in payment of the subscription price.

 

The
undersigned hereby represents and warrants to the Corporation that the undersigned (check one):

 

	[  ]	1.	(i)	is
    not, and is not exercising the Warrant for the account or benefit of, a U.S. person or a person in the United States;
	 	 	 	 
	 	 	(ii)	did
    not execute or deliver this exercise form while in the United States;
	 	 	 	 
	 	 	(iii)	delivery
    of the Common Shares will not be to an address within the United States; and
	 	 	 	 
	 	 	(iv)	has
    in all other respects complied with the terms of Regulation S of the U.S. Securities Act (“Regulation S”);
    or

 

	[  ]	 	2.	is
    the original subscriber for the Warrants, on its own behalf or on behalf of the designated beneficial subscriber (if any),
    it and such beneficial subscriber (if any) are “accredited investors” that satisfy one or more of the criteria
    set forth in Rule 501(a) of Regulation D under the U.S. Securities Act, delivered an Accredited Investor Certificate and a
    Certification of U.S. Purchaser to the Corporation in connection with the subscription for securities pursuant to which the
    Warrants were acquired and the representations, warranties and covenants made by the undersigned therein are true and correct
    on the date hereof in relation to the exercise of the Warrants; or
		 	 	 
	[  ]	 	3.	is
    tendering with this exercise form a written opinion of counsel of recognized standing in form and substance reasonably satisfactory
    to the Corporation to the effect that the Common Shares to be delivered upon exercise of the Warrants have been registered
    under the U.S. Securities Act and all applicable state securities laws of the United States or are exempt from such registration
    requirements.

 

“United
States” and “U.S. person” are as defined in Regulation S under the U.S. Securities Act.

 

The
undersigned holder understands that unless Box 1 above is checked, the certificate representing the Common Shares issued upon
exercise of this Warrant will bear the restrictive legend set forth in Section 11 of the Warrant.

 

    	 

    	 

    

 

The
undersigned hereby directs that the Common Shares subscribed for be registered and delivered as follows:

 

	Name
    in Full	Address	Number
    of Common Shares
	 	 	 
	 	 	 

 

DATED
this _____ day of _______________, 20_____.

 

	 	 	 
	 	By:	 
	 	 	 

 

    	2

    	 

    

 

Appendix
A

 

Form
of Declaration for Removal of Legend

 

	TO:	BRIACELL
    THERAPEUTICS CORP. (the “Corporation”)
	 	 
	TO:	Registrar
    and transfer agent for the shares of the Corporation

 

The
undersigned (A) acknowledges that the sale of the securities of the Corporation to which this declaration relates is being made
in reliance on Rule 904 of Regulation S under the United States Securities Act of 1933, as amended (the “1933 Act”),
and (B) certifies that (1) the undersigned is not (a) an “affiliate” of the Corporation (as that term is defined in
Rule 405 under the 1933 Act) (b) a “distributor” as defined in Regulation S or (c) an affiliate of a distributor;
(2) the offer of such securities was not made to a person in the United States and either (a) at the time the buy order was originated,
the buyer was outside the United States, or the seller and any person acting on its behalf reasonably believed that the buyer
was outside the United States, or (b) the transaction was executed on or through the facilities of the TSX Venture Exchange and
neither the seller nor any person acting on its behalf knows that the transaction has been prearranged with a buyer in the United
States; (3) neither the seller nor any affiliate of the seller nor any person acting on their behalf has engaged or will engage
in any directed selling efforts in the United States in connection with the offer and sale of such securities; (4) the sale is
bona fide and not for the purpose of “washing off” the resale restrictions imposed because the securities are “restricted
securities” (as that term is defined in Rule 144(a)(3) under the 1933 Act); (5) the seller does not intend to replace such
securities with fungible unrestricted securities; and (6) the contemplated sale is not a transaction, or part of a series of transactions,
which, although in technical compliance with Regulation S, is part of a plan or scheme to evade the registration provisions of
the U. S. Securities Act. Terms used herein have the meanings given to them by Regulation S under the 1933 Act.

 

	Dated
    _______________, 20__	X
    ______________________________________________
		Signature
    of individual (if Purchaser is an individual)
	 	 
	 	X
    ______________________________________________
	 	Authorized
    signatory (if Purchaser is not an individual)
	 	 
	 	 
	 	Name
    of Purchaser (please print)
	 	 
	 	 
	 	Name
    of authorized signatory (please print)
	 	 
	 	 
	 	Official
    capacity of authorized signatory (please print)

 

    	 

    	 

    

 

Schedule
B

 

FORM
OF TRANSFER

 

FOR
VALUE RECEIVED, the undersigned hereby sells, assigns and transfers unto __________________________________ (include name and
address of the transferee) Warrants exercisable for common shares of BriaCell Therapeutics Corp. (the “Corporation”)
registered in the name of the undersigned on the register of the Corporation maintained therefor, and hereby irrevocably appoints
_________________________________________ the attorney of the undersigned to transfer the said securities on the books maintained
by the Corporation with full power of substitution.

 

DATED
this _____ day of _______________, 20_____.

 

Signature
of Transferor guaranteed by:

 

	 	 	 
	Name
    of Bank or Trust Company:	 	Signature
    of Transferor
	 	 	 
	 	 	 
	 	 	 
	 	 	 
	 	 	 
	 	 	 
	 	 	Address
    of Transferor

 

Instructions:

 

	1.	The
    name of the transferor must correspond with the name written upon the face of this Warrant Certificate in every particular
    without any changes whatsoever.
	 	 
	2.	The
    signature of the Transferor on the Transfer Form must be guaranteed by an authorized officer of a chartered bank, trust company
    or an investment dealer who is a member of a recognized stock exchange, and the Warrantholder must pay any applicable transfer
    taxes or fees.
	 	 
	3.	If
    the Transfer Form is signed by a trustee, executor, administrator, curator, guardian, attorney, officer of a corporation or
    any person acting in a judiciary or representative capacity, the Warrant Certificate must be accompanied by evidence of authority
    to sign satisfactory to the Corporation.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00302-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00302-of-00352.parquet"}]]